Aldol condensations in pyrazino[2,1-*b*]quinazolines. Fast access to *seco*-ardeemin derivatives

Pilar Cledera, Mercedes Villacampa, Carmen Avendaño, and J. Carlos Menéndez*

Departamento de Química Orgánica y Farmacéutica, Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain

E-mail: josecm@farm.ucm.es

This paper is dedicated to Professor Julio Álvarez-Builla, on the occasion of his 65th birthday

Abstract

The reaction between 2-alkylpyrazino[2,1-*b*]quinazoline-3,6-diones and aromatic aldehydes in the presence of KO^tBu afforded the corresponding 1-arylmethylene derivatives, preferentially as the *Z* isomers. This diastereoselectivity was the result of thermodynamic control, as shown by *ab initio* calculations. These aldol reactions proceeded with partial racemization of the C-4 stereocenter, in contrast with the condensations of the related 2-acetylpyrazino[2,1-*b*]quinazoline-3,6-diones. Catalytic hydrogenation of the 1-arylmethylene derivatives obtained through these condensations afforded *cis*-1,4-disubstituted pyrazino[2,1-*b*]quinazoline-3,6-diones, normally with complete diastereoselectivity, but these reactions had compounds from partial reduction of the benzene ring as side products.

Keywords: Aldol condensation, pyrazino[2,1-*b*]quinazolines, diastereoselectivity, catalytic hydrogenation, benzene hydrogenation

Introduction

The quinazolin-4-one family of alkaloids¹ comprises about 150 compounds that have been isolated from fungi, marine organisms and higher plants. Benzo-fused derivatives of this system are also common in nature, the most important ones being pyrazino[2,1-*b*]quinazoline-3,6-diones.² This system is the key structural fragment of a group of fungal metabolites which often exhibit very interesting biological properties. The simplest member of this family of alkaloids is gyantrypine, isolated from *Aspergillus clavatus*.³ C₄-substituted compounds include members of the fumiquinazoline⁴ and fiscalin⁵ families, some of which have shown cytotoxicity and antifungal activities. More complex systems include *N*-acetylardeemin, which was isolated from

Aspergillus fischeri^{6a} and is one of the most potent known inhibitors⁷ of multi-drug resistance to antitumour compounds (MDR), which can be considered as the most important single factor that prevents the success of antitumour chemotherapy in many cancer patients.⁸ Thus, *N*-acetylardeemin potentiated the cytotoxicity of vinblastine, doxorubicin or paclitaxel in multidrug resistant human tumor cells, with a 10-fold potency with respect to verapamil, the standard anti-MDR compound. Its synthetic glycine analog and its trifluoro derivative are also potent MDR reversal agents that bind to the two main transport proteins responsible the MDR phenomenon, namely P-gp 170 and MRP.^{6b,9} The study of simplified ardeemin analogues has led to the conclusion that the pyrazino[2,1-*b*]quinazoline fragment can be considered as its pharmacophoric moiety for MDR reversal activity, which underscores the importance of this tricyclic system.¹⁰ Another interesting property of some members of the ardeemin family is their immunosuppressant activity.¹¹

Figure 1. Representative pyrazino[2,1-*b*]quinazoline alkaloids.

Results and Discussion

Due to the pharmacological interest of pyrazino[2,1-*b*]quinazolines as MDR modulators,^{10a} we became interested in 1-arylmethylene derivatives of the parent system **1**, which can be considered as *seco*-analogues of ardeemin. Since MDR reversal activity normally correlates well with lipophilicity,⁸ we designed compounds **1** to be *N*-substituted. Compounds **1** where R² = H have been obtained by von Niementowsky or aza Wittig reactions from 6-arylmethylene-2,5-piperazinediones,¹² which were in turn obtained by base-catalyzed condensation of 1,4-diacetyl-2,5-piperazinedione with aromatic aldehydes, a reaction that takes place with anchimeric assistance from the *N*-acetyl substituent and is accompanied by *N*-deacetylation. Since regioselective *N*-alkylation is difficult due to the steric hindrance caused by the arylmethylene substituent and may be hampered by competing deprotonation at C-4, the most direct approach to our target compounds **1** would be one based on the direct aldol condensation of compounds **2** with aromatic aldehydes. These starting materials were known compounds,^{12b,13} but we have developed an improved preparation of **2a** based on an acylation/aza-Wittig strategy (see

Experimental). Furthermore, the availability of **1** would allow the simple preparation of compounds **3** in an alternative approach to the one involving the base-promoted alkylation of **2**,¹⁴ which has disadvantages such as lack of diastereoselectivity and the isolation of double alkylation products (Scheme 1). The *cis*-compounds **3** are interesting in spite of having the opposite relative configuration to ardeemin because it has been shown for another family of simplified analogues of the ardeemin ABCD ring system that compounds with an opposite configuration to the natural product at the alanine stereocenter had improved activity as MDR reversors.^{10b}

Scheme 1

The results of the systematic study¹⁵ of the condensation of compounds **2a-c** with several aromatic aldehydes derived from benzaldehyde and indole-3-carbaldehyde in the presence of a slight excess of potassium *tert*-butoxide (KO^tBu) are shown in Scheme 2 and Table 1. The assignment of the *Z* configuration to the major products was based on the chemical shift of the vinylic proton, which was observed at *ca.* 7.40 ppm due to a deshielding effect caused by the neighbouring C=N group, while for the *E* isomers this signal was observed at about 6.70 ppm. This assignment was confirmed by NOE effects in representative compounds.

Scheme 2

Table 1. Scope and yields of the reaction between compounds **2** and aldehydes

Entry	Starting material	Product	Ar	R^2	Yield of (Z)- 1 , %	Yield of (E)- 1 , %
1	2a	1a	4-ClC ₆ H ₄	(S)-CH ₃	73	26
2	2b	1b	4-ClC ₆ H ₄	(R)-CH ₃	75	24
3	2c	1c	4-ClC ₆ H ₄	CH ₂ CH ₂ C ₆ H ₅	48	46
4	2a	1d	4-BrC ₆ H ₄	CH ₃	45	22
5	2a	1e	4-NO ₂ C ₆ H ₄	CH ₃	71	3 ^a
6	2a	1f	3,4-Cl ₂ C ₆ H ₃	CH ₃	62	23
7	2a	1g	2,4-F ₂ C ₆ H ₃	CH ₃	87	0
8	2a	1h	1-Benzyl-3-indolyl	CH ₃	53	38 ^b
9	2a	1i	1-Tosyl-3-indolyl	CH ₃	36	16
19	2a	1j	4-MeOC ₆ H ₄	H	63	16 ^c

^aTogether with 10% of **4**. ^bMeasured by NMR of the crude reaction product. ^cTogether with 20% of **5**.

Some of the condensation reactions afforded significant amounts of side products. In the case of the reaction between **2a** and 4-nitrobenzaldehyde, we isolated the 1-oxo derivative of the starting material (compound **4**). As shown in Scheme 3, the formation of **4** is probably due to the fact that the C-1 position of **2a** allows the generation of a radical stabilized by captodative effect¹⁶ (intermediate **6**), which can then react with a molecule of oxygen¹⁷ to give **7**. Attack of this radical to a fresh molecule of **2a** regenerates **6**, closing the propagation cycle, and affords hydroperoxide **8**. Finally, loss of a molecule of water from **8** explains the formation of the observed product **4**. The fact that this side reaction was only observed in the reaction with 4-nitrobenzaldehyde may be related to the ability of nitro groups to act as intermediates in one-electron transfer reactions.¹⁸ This observation leads us to favour the explanation summarized in Scheme 3 over an alternative one based on the reaction of an anion at C-1 followed by reaction

with oxygen. Radical formation at C-4 would also be possible, in principle, but it would lead to racemization, which has not been observed.

Scheme 3

Another unexpected product was obtained in the reaction between **2a** and 4-methoxybenzaldehyde, in which case compound **1j** was accompanied by compound **5** in 1.5:1 *Z/E* ratio. The formation of **5** can be explained by the formation of the dipole-stabilized carbanion¹⁹ **9** by deprotonation of the *N*-methyl carboxamide portion in the initial reaction product **1j**. The reaction of **9** with the starting aldehyde, followed by oxidation, explains the formation of **5** (Scheme 4). In agreement with this explanation, only traces of **5** were isolated when the reactions were carried out in the presence of an equimolecular amount of base. The low *Z/E* diastereoselectivity observed for **5** agrees with the one observed for the *N*-phenetyl derivative **1c** (*ca.* 1:1), which was much lower than that found for *N*-methyl derivatives. This difference is discussed below (see table 3, Figure 2 and accompanying text).

Scheme 4

In order to increase the synthetic scope of our reaction, we decided to study the related process starting from *N*-acetyl derivatives of the starting material. This transformation is related to the analogous reaction between *N*-acetyl-2,5-piperazinediones and aldehydes, which is well preceded in the literature and is known to be accompanied by *N*-deacetylation and to lead exclusively to products with *Z* configuration. As starting material, we selected compound **2d**, which is available through a method developed during our studies on the total synthesis of gyantripine.^{3b} According to the literature precedent on the simpler piperazinedione systems, treatment of **2d** with 4-chlorobenzaldehyde in the presence of KO^tBu at room temperature afforded an excellent yield of the deacetylated condensation product **1k**, which was isolated exclusively as the *Z* isomer. The mechanism proposed for this transformation is summarized in Scheme 5, and is based on the one commonly accepted for the related reaction of *N*-acetyl-2,5-piperazinediones.²⁰

Scheme 5

Reactions involving the use of a strong base can potentially affect the stereocenter adjacent to the carbonyl. When compounds **1a-j** were examined using either ^1H -NMR in the presence of (+)-europium tris[3-(trifluoromethylhydroxymethylene)]camphorate ($\text{Eu}(\text{hfc})_3$) or by HPLC using a cellulose carbamate chiral column, enantiomeric ratios were normally poor (Table 2), although this will not probably constitute a problem in terms of bioactivity, since MDR inhibition is not normally stereospecific.⁸ Replacement of KO^tBu by cesium carbonate, a much weaker base, did not improve this result, as verified for the case of compound **1a**. Comparison of the results summarized in Tables 1 and 2 suggests a correlation between *Z:E* and enantiomeric ratios, since reactions with better *Z* selectivity are also more enantioselective (compare entries 5 and 7 of both Tables with the other results). On the other hand, the *N*-unsubstituted compound **1k** was obtained as a single enantiomer as in the case of aldol condensations starting from (*S*)-1,4-diacetyl-3-methyl-2,5-piperazinedione, using KO^tBu as a base, in which the stereocenter maintains its integrity within the limits of detection of ^1H -NMR in the presence of a chiral shift reagent.^{12a 21} This behaviour may be explained by considering that an aldol reaction at the position adjacent to a *N*-acetyl substituent is accompanied by its deacetylation, which liberates an ionizable NH group at the end of the process that hampers a second deprotonation at the stereocenter. In the case of compound **1k**, the absence of racemization is probably due to the existence of a free NH group that makes more probable the formation of a conjugated anion **10** rather than **11**, which is the one required for the inversion of the stereocenter (Scheme 6).

Table 2. Enantiomeric ratios found for the *Z* isomers of compounds **1**

Entry	Compound	Ar	R ²	e.r.	Technique
1	1a	4-ClC ₆ H ₄	CH ₃	2 : 1	HPLC ¹ H-NMR
2	1b	4-ClC ₆ H ₄	CH ₃	2 : 1	HPLC ¹ H-NMR
3	1c	4-ClC ₆ H ₄	CH ₂ CH ₂ C ₆ H ₅	1 : 1	HPLC ¹ H-NMR
4	1d	4-BrC ₆ H ₄	CH ₃	3 : 1	¹ H-NMR
5	1e	4-NO ₂ C ₆ H ₄	CH ₃	8 : 1	HPLC ¹ H-NMR
6	1f	3,4-Cl ₂ C ₆ H ₃	CH ₃	1.5 : 1	¹ H-NMR
7	1g	2,4-F ₂ C ₆ H ₃	CH ₃	8 : 1	HPLC ¹ H-NMR
8	1h	1-Benzyl-3-indolyl	CH ₃	2 : 1	¹ H-NMR
9	1j	4-MeOC ₆ H ₄	CH ₃	1.5 : 1	HPLC ¹ H-NMR
10	1k	4-ClC ₆ H ₄	H	> 98 : 2	HPLC

Scheme 6

In order to allow a meaningful comparison between piperazinediones and compounds **1a-j**, we studied the aldol condensation of a *N*-substituted-2,5-piperazinedione, and to this end we prepared compound **13** by acetylation of the known²² *cyclo*-(sarcosine-L-alanine) **12**. Treatment of **13** with 4-chlorobenzaldehyde under our usual conditions afforded a mixture of the *Z* and *E* condensation products **14** in low yields because of base-promoted deacetylation of the starting material. In contrast with our previous observations on compounds **1a-j**, the major product from this mixture was found to contain a single enantiomer by ¹H-NMR in the presence of Eu(hfc)₃. This difference in behavior can be attributed to fact that in the case of **14** the acidic proton responsible for the racemization is more hindered due to the conformational freedom of the

neighbouring *N*-acetyl substituent, whereas in the rigid compounds **1** this proton is more accessible (Scheme 7).

Scheme 7

The *Z*-selectivity of the aldol reactions was attributed to thermodynamic control, since the *Z* isomers were found to be more stable according to *ab initio* calculations at the HF 6-31G level. The results obtained are collected in Table 3, which shows that the differences in stability between the *Z* and *E* isomers correlate well with the experimental diastereomeric ratios. Thus, in the case of **1a**, for which the experimental d.r. was *ca.* 3:1, the *Z* isomer was more stable than the *E* in $2.88\text{ kcal.mol}^{-1}$ (entry 1). This difference was only $0.92\text{ kcal.mol}^{-1}$ in case of the *N*-phenethyl derivative **1c** (entry 2), where the *Z* and *E* isomers were isolated in equimolecular amounts, probably due to an increased repulsion between the bulkier *N*-substituent and the arylmethylene side chain. The calculated differences in stability were much higher (*ca.* 6 kcal.mol^{-1}) for the *N*-unsubstituted compounds **1k** and **14**, for which the *E* isomer was not observed (entries 3 and 4). As shown in Figure 2 for the *ab initio*-minimized structures, the lower stability of the *E* isomers can be attributed to repulsive interactions between the C-1 and C-4 substituents. In the case of compound (E)-**1b**, having an *R* configuration at C-4, this interaction cannot take place. In this case, the conformation of the piperazine ring changes to the other possible boat structure in order to avoid the repulsive interaction between the C_4 -methyl and $\text{C}_6=\text{O}$ groups, and this brings the arylmethylene unit close to the tricyclic system, explaining the lower stability of this compound compared with its (*Z*) isomer.

Table 3. Calculated energy differences between the *Z* and *E* isomers of selected compounds

Entry	Compounds	ΔE , kcal.mol ⁻¹ (<i>Z</i> – <i>E</i>)	d.r.
1	(<i>Z</i>)- 1a / (<i>E</i>)- 1a	2.88	73 : 26
2	(<i>Z</i>)- 1b / (<i>E</i>)- 1b	2.87	75 : 24
3	(<i>Z</i>)- 1c / (<i>E</i>)- 1c	0.92	51 : 49
4	(<i>Z</i>)- 1k / (<i>E</i>)- 1k	6.05	100 : 0
5	(<i>Z</i>)- 14 / (<i>E</i>)- 14	6.21	100 : 0

Figure 2

With compounds **1** in hand, we studied their catalytic hydrogenation, which afforded the *cis* 1,4-disubstituted compounds **3** in a fully diastereoselective fashion. Since the (*Z*) and (*E*) isomers of compound **1a**, not unexpectedly, gave very similar results, we subsequently limited our study to the major *Z* isomers (Scheme 8, Table 4). In spite of the mild conditions employed, compounds **3** were accompanied by varying amounts of side products **15**, arising from the reduction of two bonds of the benzene ring, which were the sole products when prolonged reaction times were used (see the reduction of **1j**). This behavior may be explained by assuming that the strong conjugation between the amidine and carbonyl groups through the intermediate double bond diminishes the aromaticity of the benzene ring, allowing its partial reduction.²³

Scheme 8

Table 4. Scope and yields of the catalytic hydrogenation of compounds **1**

Starting material	Ar	R ²	Time, h	Yield of 3 , %	Yield of 15 , %
(Z)- 1a	4-ClC ₆ H ₄	CH ₃	6	63	17
(E)- 1a	4-ClC ₆ H ₄	CH ₃	6	57	15
(Z)- 1c	4-ClC ₆ H ₄	CH ₂ CH ₂ Ph	6	51	44
(Z)- 1d	4-BrC ₆ H ₄	CH ₃	6	56	0
(Z)- 1f	3,4-Cl ₂ C ₆ H ₃	CH ₃	6	51	0
(Z)- 1g	2,4-F ₂ C ₆ H ₃	CH ₃	6	50 ^a	0
(Z)- 1h	1-Benzyl-3-indolyl	CH ₃	16	86	0
(Z)- 1i	1-Tosyl-3-indolyl	CH ₃	6	77	0
(Z)- 1j	4-MeOC ₆ H ₄	CH ₃	6	48	30
			16	0	83

^aBased on unrecovered **1g**; isolated yield was 30%.

Interestingly, the diastereoselectivity of the reaction was lost when the *N*-unsubstituted substrate **1k** was employed, as shown in Scheme 9. This observation is in sharp contrast with the results described in the literature for similar hydrogenations of arylmethylene-2,5-piperazinediones, which give *cis* products exclusively. To discard any operator- or equipment-associated bias, we carried out the catalytic hydrogenation of the known compound **17**^{12a} and found that, as expected, it afforded exclusively the *cis*-disubstituted compound **18**.

The loss of diastereoselectivity in the catalytic hydrogenation of **1k** in comparison with that of **17** can be explained by assuming that both the α and β faces of the additional aromatic ring interact with the palladium catalyst, partially compensating for the steric hindrance due to the C₄-alkyl substituent. As shown in Figure 3, in the case of *N*-substituted compounds **1a-j**, steric compression between the arylmethylene and *N*-alkyl groups causes a deviation of these substituents from planarity (see also Figure 2), contributing to the blockade of the β face and overriding the effect of the bonding interaction due to the aromatic ring.

Scheme 9

Figure 3

Conclusions

The direct aldol condensation of pyrazino[2,1-*b*]quinazoline-3,6-diones, followed or not by catalytic hydrogenation of the exocyclic double bond, provides a very concise route to *seco*-ardeemin analogues. These reactions show some significant differences with the ones starting from piperazinedione derivatives, particularly in terms of diastereoselectivity and potential for racemization of carbonyl-adjacent stereocenters. In some cases, the catalytic hydrogenation of 1-arylmethylenepyrazino[2,1-*b*]quinazoline-2,6-diones was accompanied by the unexpected reduction of two double bonds of the benzene ring.

Experimental Section

General. All reagents (Panreac, Probus, Scharlau, Merck, Fluka, Aldrich) and solvents (SDS) were of commercial quality and were used as received. The expression *petroleum ether* refers to the 40-60 °C bp fraction. Reactions were monitored by thin layer chromatography, on aluminium plates coated with silica gel with fluorescent indicator (Scharlau Cf 530, Macherey-Nagel Alugram Sil G/UV₂₅₄). Separations by flash chromatography were performed on silica gel (SDS 60 ACC 40-63 mm, Scharlau Ge 048). Melting points were measured on a Reichert 723 hot stage microscope, and are uncorrected. Optical rotations were determined in a Perkin-Elmer 240 polarimeter. Infrared spectra were recorded on a Perkin Elmer Paragon 1000 FT-IR spectrophotometer, with all compounds examined as thin films on NaCl disks (oils) or KBr pellets (solids). NMR spectra were obtained on Bruker Avance 250 spectrometer operating at 250 MHz for ¹H and 63 MHz for ¹³C (CAI de Resonancia Magnética Nuclear, Universidad Complutense). Elemental analyses were determined by the CAI de Microanálisis Elemental, Universidad Complutense, using a Leco 932 CHNS combustion microanalyzer. HPLC analyses were carried out with a Constametric[®] 4100 instrument fitted with a UV/Visible detector and a Chiralcel-OD (Daicel Chemical Ind., LTD, 0.46 x 25 cm) column.

(4*S*)-2,4-Dihydro-2,4-dimethyl-1*H*-pyrazino[2,1-*b*]quinazoline-3,6-dione (2a). To (3*S*)-1,3-dimethyl-2,5-piperazinedione²⁰ (1 g, 7.040 mmol), dissolved in dry THF (50 mL), was added a 0.5M solution of potassium hexamethyldisilazide in dry toluene (21 mL, 10.5 mmol) at -78 °C and under an argon atmosphere. After stirring the mixture for 15 min at the same temperature, a solution of 2-azidobenzoyl chloride (obtained as previously described^{12a} from 4.5 g (24.45 mmol) of 2-azidobenzoic acid and 18 mL of thionyl chloride) in dry THF (50 mL) was added and the reaction mixture was stirred at room temperature for 16 h, and then evaporated. The residue was chromatographed on silica gel, eluting with a 6:1 petroleum ether-ethyl acetate mixture, to yield 2.010 g (99%) of (6*S*)-1-(2-azidobenzoyl)-4,6-dimethylpiperazine-2,5-dione. A solution of this compound (1.039 g, 3.607 mmol) and tributylphosphine (0.914 mL, 3.692 mmol) in dry toluene (25 mL) was stirred at rt for 3 h under an argon atmosphere. The reaction was then

evaporated under reduced pressure. The residue was purified by fast chromatography on silica gel, eluting with a 2:1 petroleum ether-dichloromethane mixture, yielding 0.587 g (71%) of **2a**, as a white solid, with spectral data identical to the ones found in the literature.¹³ **(6S)-1-(2-Azidobenzoyl)-4,6-dimethylpiperazine-2,5-dione**. Pale brown solid; mp 115-117 °C; $[\alpha]_D^{25} = -60.0$ (c 0.015, CHCl₃); IR (KBr) ν : 2130.0 (N₃), 1730.0 and 1674.6 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 7.47 (t, 1H, $J = 7.5$ Hz, H-5'), 7.36 (d, 1H, $J = 7.5$ Hz, H-6'), 7.23-7.12 (m, 2H, H-3',4'), 5.06 (q, 1H, $J = 7.2$ Hz, H-6), 4.20 (1d, 1H, $J = 18.4$ Hz, H-3), 3.95 (d, 1H, $J = 18.4$ Hz, H-3), 3.04 (s, 3H, NCH₃), 1.58 (d, 3H, $J = 7.2$ Hz, C₆-CH₃). ¹³C-NMR (CDCl₃) δ 167.5 (C-2), 167.3 (C-5), 165.9 (CO α), 136.5 (C-1'), 136.5 (C-2'), 131.7 (C-4'), 128.1 (C-6'), 125.0 (C-5'), 118.1 (C-3'), 56.5 (C-6), 53.8 (C-3), 33.6 (NCH₃), 18.5 (C₃-CH₃). Anal. Calc. for C₁₃H₁₃N₅O₃: C, 54.35; H, 4.56; N, 24.38. Found: C, 54.27; H, 4.87; N, 24.14.

(4S,1Z)- and (4S,1E)-1-(4-Chlorobenzylidene)-2,4-dihydro-2,4-dimethyl-1H-pyrazino[2,1-b]quinazoline-3,6-dione, (Z)-1a and (E)-1a. To a solution of **2a** (0.30 g, 1.234 mmol) and 4-chlorobenzaldehyde (0.26 g, 1.851 mmol) in dry DMF (3 mL) at 0 °C and under an argon atmosphere, a 1M KO^tBu/^tBuOH solution (1.3 mL, 1.3 mmol) was added dropwise. The mixture was stirred at rt for 16 h. Then, the reaction was neutralized with acetic acid, poured onto ice and extracted with ethyl acetate. The combined organic extracts were dried (anhydrous Na₂SO₄) and evaporated. The residue was purified by fast chromatography on silica gel, eluting with a 1:5 ethyl acetate-petroleum ether mixture, yielding 0.331 g (73%) of **(Z)-1a** and 0.130 g (26%) of **(E)-1a**.

Data for (Z)-1a. Yellow solid; mp 202-204 °C; IR (KBr) ν 1688.2 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 8.28 (d, 1H, $J = 8.1$ Hz, H-7), 7.82-7.70 (m, 2H, H-9,10), 7.50 (t, 1H, $J = 8.1$ Hz, H-8), 7.45 (d, 2H, $J = 7.9$ Hz, H-2',6'), 7.42 (s, 1H, H α), 7.29 (d, 2H, $J = 7.9$ Hz, H-3',5'), 5.68 (q, 1H, $J = 7.1$ Hz, H-4), 2.97 (s, 3H, NCH₃), 1.63 (d, 3H, $J = 7.1$ Hz, C₄-CH₃); ¹³C-NMR (CDCl₃) δ 167.9 (C-3), 159.9 (C-6), 151.4 (C-11a), 147.6 (C-10a), 134.2 (C-4'), 131.1 (C-9), 130.9 (C-1'), 129.8 (C-2',6'), 128.3 (C-3',5'), 127.9 (C-7), 127.5 (C-8), 126.7 (C-10), 126.3 (C-1), 119.6 (C α), 120.4 (C-6a), 52.1 (C-4), 35.2 (NCH₃), 17.8 (C₄-CH₃). Anal. Calc. for C₂₀H₁₆ClN₃O₂: C, 65.67; H, 4.41; N, 11.49. Found: C, 65.55; H, 4.40; N, 11.45.

Data for (E)-1a. Yellow solid; mp 137-139 °C; IR (KBr) ν 1682.7 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 8.27 (d, 1H, $J = 8.0$ Hz, H-7), 7.52-7.22 (m, 5H, H-10,2',3',5',6'), 7.58 (t, 1H, $J = 8.0$ Hz, H-8), 7.69 (t, 1H, $J = 7.9$ Hz, H-9), 6.65 (s, 1H, H α), 5.62 (q, 1H, $J = 7.1$ Hz, H-4), 3.40 (s, 3H, NCH₃), 1.65 (d, 3H, $J = 7.1$ Hz, C₄-CH₃); ¹³C-NMR (CDCl₃) δ : 166.8 (C-3), 159.8 (C-6), 146.8 (C-11a), 144.9 (C-10a), 134.1 (C-4'), 134.9 (C-9), 132.6 (C-1'), 131.2 (C-2',6'), 129.1 (C-1), 128.3 (C-3',5'), 128.0 (C-7), 127.8 (C-8), 126.9 (C-10), 121.6 (C α), 120.7 (C-6a), 51.8 (C-4), 31.8 (NCH₃), 18.3 (C₄-CH₃). Anal. Calc. for C₂₀H₁₆ClN₃O₂: C, 65.67; H, 4.41; N, 11.49. Found: C, 65.73; H, 4.42; N, 11.44.

(4R,1Z)- and (4R,1E)-1-(4-Chlorobenzylidene)-2,4-dihydro-2,4-dimethyl-1H-pyrazino[2,1-b]quinazoline-3,6-dione, (Z)-1b and (E)-1b. Obtained as described for **1a**, from compound **2b** (0.20 g, 0.823 mmol), 4-chlorobenzaldehyde (0.173 g, 1.234 mmol), dry DMF (2 mL) and a 1M KO^tBu/^tBuOH solution (0.9 mL, 0.9 mmol).

Data for (Z)-1b. Yield 0.225 g, 75%; yellow solid (after chromatography eluting with 1:8 EtOAc/petroleum ether); mp 203-205 °C. The spectral data are identical to those of compound (Z)-1a. Anal. Calc. for C₂₀H₁₆ClN₃O₂: C, 65.67; H, 4.41; N, 11.49. Found: C, 65.63; H, 4.40; N, 11.46.

Data for (E)-1b. Yield 0.048 g, 24%; yellow solid (after chromatography eluting with 1:8 EtOAc/petroleum ether); mp 136-138 °C. The spectral data are identical to those of compound (E)-1a. Anal. Calc. for C₂₀H₁₆ClN₃O₂: C, 65.67; H, 4.41; N, 11.49. Found: C, 65.64; H, 4.45; N, 11.44.

(4S,1Z)- and (4S,1E)-1-(4-Chlorobenzylidene)-2,4-dihydro-4-methyl-2-phenethyl-1H-pyrazino[2,1-b]quinazoline-3,6-dione, (Z)-1c and (E)-1c. Obtained as described for 1a, from compound 2c (0.20 g, 0.60 mmol), 4-chlorobenzaldehyde (0.126 g, 0.90 mmol), dry DMF (2 mL) and a 1M KO^tBu/^tBuOH solution (0.6 mL, 0.6 mmol).

Data for (Z)-1c. Yield 0.131 g, 48%; white crystals (after chromatography eluting with 1:6 EtOAc/petroleum ether); mp 205-207 °C; IR (KBr) ν 1687.5 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 8.27 (d, 1H, *J* = 8.0 Hz, H-7), 7.79 (t, 1H, *J* = 8.0 Hz, H-9), 7.66 (d, 1H, *J* = 7.9 Hz, H-10), 7.50 (t, 1H, *J* = 8.0 Hz, H-8), 7.26 (m, 1H, H α), 6.93 (t, 2H, *J* = 7.1 Hz, H-2',6'), 6.85 (d, 2H, *J* = 7.1 Hz, H-3',5'), 7.38 (s, 5H, Ph), 5.60 (q, 1H, *J* = 7.2 Hz, H-4), 4.44-4.33 (m, 1H, CH₂CH₂Ph), 3.21-3.05 (m, 1H, CH₂CH₂Ph), 2.81-2.61 (m, 2H, CH₂CH₂Ph), 1.54 (d, 3H, *J* = 7.2 Hz, C₄-CH₃); ¹³C-NMR (CDCl₃) δ 167.9 (C-3), 159.6 (C-6), 147.6 (C-11a), 147.4 (C-10a), 136.8 (C-1''), 135.1 (C-4'), 134.6 (C-9), 131.4 (C-1'), 130.3 (C-2',6'), 130.1 (C-1), 129.1 (C-3',5'), 128.6 (C-2'',6''), 128.1 (C-4''), 127.3 (C-3'',5''), 127.1 (C-7), 126.8 (C-8), 126.5 (C-10), 121.7 (C-6a), 120.1 (C α), 51.7 (C-4), 47.5 (CH₂CH₂Ph), 33.1 (CH₂CH₂Ph), 17.1 (C₄-CH₃); Anal. Calc. for C₂₇H₂₂ClN₃O₂: C, 71.13; H, 4.86; N, 9.22. Found: C, 70.89; H, 4.90; N, 9.18.

Data for (E)-1c. Yield 0.125 g, 46%; white crystals (after chromatography eluting with 1:6 EtOAc/petroleum ether); mp 130-132 °C; IR (KBr) ν 1683.5 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 8.26 (d, 1H, *J* = 7.9 Hz, H-7), 7.69 (t, 1H, *J* = 7.9 Hz, H-9), 7.38-6.87 (m, 10H, H-10,2',3',5',6', Ph), 7.48 (t, 1H, *J* = 7.9 Hz, H-8), 6.54 (m, 1H, H α), 5.55 (q, 1H, *J* = 7.1 Hz, H-4), 4.35-4.25 (m, 1H, CH₂CH₂Ph), 4.10-4.00 (m, 1H, CH₂CH₂Ph), 3.15-3.00 (m, 2H, CH₂CH₂Ph), 1.63 (d, 3H, *J* = 7.1 Hz, C₄-CH₃); ¹³C-NMR (CDCl₃) δ 166.4 (C-3), 159.6 (C-6), 146.7 (C-11a), 144.9 (C-10a), 137.8 (C-1''), 134.7 (C-4'), 133.9 (C-9), 132.2 (C-1'), 130.9 (C-2',6'), 130.2 (C-1), 128.7 (C-3',5'), 128.6 (C-2'',6''), 128.5 (C-4''), 128.1 (C-3'',5''), 127.5 (C-7), 126.8 (C-8), 126.6 (C-10), 122.5 (C-6a), 120.5 (C α), 51.70 (C-4), 46.7 (CH₂CH₂Ph), 33.1 (CH₂CH₂Ph), 17.6 (C₄-CH₃). Anal. Calc. for C₂₇H₂₂ClN₃O₂: C, 71.13; H, 4.86; N, 9.22. Found: C, 70.98; H, 4.89; N, 9.20.

(4S,1Z)- and (4S,1E)-1-(4-Bromobenzylidene)-2,4-dihydro-2,4-dimethyl-1H-pyrazino[2,1-b]quinazoline-3,6-dione, (Z)-1d and (E)-1d. Obtained as described for 1a, from compound 2a (0.20 g, 0.822 mmol), 4-bromobenzaldehyde (0.288 g, 1.233 mmol), dry DMF (2 mL) and a 1M KO^tBu/^tBuOH solution (0.9 mL, 0.9 mmol).

Data for (Z)-1d. Yield 0.150 g, 45%; yellow solid (after chromatography eluting with 1:3 EtOAc/petroleum ether); mp 205-207 °C; IR (KBr) ν : 1692.7 (CO) cm⁻¹; ¹H-NMR (DMSO-*d*₆) δ 8.05 (d, 1H, *J* = 8.1 Hz, H-7), 7.62-7.50 (m, 2H, H-9,10), 7.29 (t, 1H, *J* = 8.1 Hz, H-8), 7.25 (d,

2H, $J = 8.0$ Hz, H-2',6'), 7.21 (s, 1H, H α), 7.09 (d, 2H, $J = 8.0$ Hz, H-3',5'), 5.40 (q, 1H, $J = 7.1$ Hz, H-4), 2.78 (s, 3H, NCH₃), 1.43 (d, 3H, $J = 7.1$ Hz, C₄-CH₃); ¹³C-NMR (DMSO-*d*₆) δ 168.2 (C-3), 160.1 (C-6), 147.8 (C-11a), 141.0 (C-10a), 135.2 (C-1'), 132.6 (C-9), 132.6 (C-4'), 132.3 (C-2',6'), 131.1 (C-3',5'), 127.8 (C-7), 127.7 (C-8), 127.3 (C-10), 123.5 (C-1), 121.5 (C-6a), 120.6 (C α), 52.3 (C-4), 35.5 (NCH₃), 17.8 (C₄-CH₃). Anal. Calc. for C₂₀H₁₆BrN₃O₂: C, 58.55; H, 3.93; N, 10.24. Found: C, 58.32; H, 4.01; N, 10.19.

Data for (E)-1d. Yield 0.072 g, 22%; yellow solid (after chromatography eluting with 1:3 EtOAc/petroleum ether); mp 120-122 °C; IR (KBr) ν : 1688.5 (CO) cm⁻¹; ¹H-NMR (DMSO-*d*₆) δ : 8.08 (d, 1H, $J = 7.6$ Hz, H-7), 7.53-7.42 (m, 2H, H-9,10), 7.35 (t, 1H, $J = 7.6$ Hz, H-8), 7.25 (d, 2H, $J = 8.0$ Hz, H-2',6'), 7.09 (d, 2H, $J = 8.0$ Hz, H-3',5'), 6.45 (s, 1H, H α), 5.40 (q, 1H, $J = 7.1$ Hz, H-4), 3.22 (s, 3H, NCH₃), 1.44 (d, 3H, $J = 7.1$ Hz, C₄-CH₃); ¹³C-NMR (DMSO-*d*₆) δ : 166.3 (C-3), 159.7 (C-6), 146.7 (C-11a), 144.8 (C-10a), 135.3 (C-1'), 133.1 (C-9), 131.6 (C-4'), 131.3 (C-2',6'), 131.1 (C-3',5'), 127.8 (C-7), 127.7 (C-8), 126.7 (C-10), 122.1 (C-1), 121.5 (C-6a), 120.7 (C α), 51.7 (C-4), 31.7 (NCH₃), 18.2 (C₄-CH₃). Anal. Calc. for C₂₀H₁₆BrN₃O₂: C, 58.55; H, 3.93; N, 10.24. Found: C, 58.58; H, 4.00; N, 10.21.

(4S,1Z)- and (4S,1E)-2,4-Dihydro-2,4-dimethyl-1-(4-nitrobenzylidene)-1H-pyrazino[2,1-b]quinazoline-3,6-dione, (Z)-1e and (E)-1e, and (4S)-2,4-dihydro-2,4-dimethyl-pyrazino[2,1-b]quinazoline-1,3,6-trione (4). Obtained as described for **1a**, from compound **2a** (0.20 g, 0.823 mmol), 4-nitrobenzaldehyde (0.186 g, 1.231 mmol), dry DMF (2 mL) and a 1M KO^tBu/^tBuOH solution (0.9 mL, 0.9 mmol).

Data for (Z)-1e. Yield 0.218 g, 71%; orange solid (in this case, compound (Z)-1e precipitated when the reaction mixture was poured on ice); mp 295-297 °C; IR (KBr) ν : 1698.5 (CO) cm⁻¹; ¹H-NMR (DMSO-*d*₆) δ 8.30 (d, 2H, $J = 8.1$ Hz, H-3',5'), 8.17 (d, 1H, $J = 8.0$ Hz, H-7), 7.90 (t, 1H, $J = 8.0$ Hz, H-9), 7.79-7.72 (m, 3H, H-10,2',6'), 7.58 (t, 1H, $J = 8.0$ Hz, H-8), 7.51 (s, 1H, H α), 5.37 (q, 1H, $J = 7.1$ Hz, H-4), 2.84 (s, 3H, NCH₃), 1.54 (d, 3H, $J = 7.1$ Hz, C₄-CH₃); ¹³C-NMR (DMSO-*d*₆) δ 167.3 (C-3), 166.2 (C-6), 159.3 (C-11a), 147.5 (C-10a), 146.8 (C-4'), 135.1 (C-9), 131.2 (C-1'), 130.9 (C-2',6'), 127.6 (C-7), 127.5 (C-8), 126.6 (C-10), 123.9 (C-3',5'), 122.9 (C-1), 120.6 (C-6a), 118.3 (C α), 51.3 (C-4), 35.7 (NCH₃), 17.8 (C₄-CH₃). Anal. Calc. for C₂₀H₁₆N₄O₄: C, 63.82; H, 4.28; N, 14.89. Found: C, 63.91; H, 4.25; N, 14.82.

Data for (E)-1e. Yield 0.008 g, 3%; orange solid (after chromatography eluting with 1:6 EtOAc/petroleum ether); mp 110-112 °C; IR (KBr) ν : 1687.7 (CO) cm⁻¹; ¹H-NMR (DMSO-*d*₆) δ : 8.27 (d, 2H, $J = 7.8$ Hz, H-3',5'), 8.13 (d, 1H, $J = 8.1$ Hz, H-7), 8.00 (d, 2H, $J = 7.8$ Hz, H-2',6'), 7.86 (t, 1H, $J = 8.1$ Hz, H-9), 7.63 (t, 1H, $J = 8.1$ Hz, H-8), 7.53 (d, 1H, $J = 8.1$ Hz, H-10), 6.69 (s, 1H, H α), 5.59 (q, 1H, $J = 6.9$ Hz, H-4), 3.41 (s, 3H, NCH₃), 1.64 (d, 3H, $J = 6.9$ Hz, C₄-CH₃); ¹³C-NMR (DMSO-*d*₆) δ : 168.9 (C-3), 159.7 (C-6), 157.6 (C-11a), 147.7 (C-10a), 146.8 (C-4'), 135.8 (C-9), 131.1 (C-1'), 130.8 (C-2',6'), 130.4 (C-7), 130.2 (C-8), 130.1 (C-10), 127.2 (C-3',5'), 124.3 (C-1), 123.6 (C-6a), 119.5 (C α), 51.9 (C-4), 36.0 (NCH₃), 18.4 (C₄-CH₃). Anal. Calc. for C₂₀H₁₆N₄O₄: C, 63.82; H, 4.28; N, 14.89. Found: C, 63.77; H, 4.24; N, 14.86.

Data for (4). Yield 0.021 g, 10%; white solid (after chromatography eluting with 1:6 EtOAc/petroleum ether); mp 166-168 °C; [α]_D²⁵ = - 3.3 (*c* 0.3, CHCl₃);²⁴ IR (KBr) ν : 1686.0

(CO) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 8.32 (d, 1H, $J = 8.0$ Hz, H-7), 8.02 (d, 1H, $J = 8.0$ Hz, H-10), 7.89 (t, 1H, $J = 8.0$ Hz, H-8), 7.64 (t, 1H, $J = 8.0$ Hz, H-9), 5.60 (q, 1H, $J = 7.0$ Hz, H-4), 3.42 (s, 3H, NCH_3), 1.73 (d, 3H, $J = 7.0$ Hz, $\text{C}_4\text{-CH}_3$); $^{13}\text{C-NMR}$ (CDCl_3) δ 168.4 (C-3), 159.2 (C-6), 158.2 (C-1), 157.1 (C-11a), 146.3 (C-10a), 135.3 (C-9), 129.7 (C-7), 129.6 (C-8), 126.8 (C-10), 121.6 (C-6a), 52.5 (C-4), 27.9 (NCH_3), 21.0 ($\text{C}_4\text{-CH}_3$). Anal. Calc. for $\text{C}_{13}\text{H}_{11}\text{N}_3\text{O}_3$: C, 60.70; H, 4.31; N, 16.33. Found: C, 60.62; H, 4.36; N, 16.32.

(4*S*,1*Z*)- and (4*S*,1*E*)-1-(3,4-Dichlorobenzylidene)-2,4-dihydro-2,4-dimethyl-1*H*-pyrazino[2,1-*b*]quinazoline-3,6-dione, (Z)-1f and (E)-1f. Obtained as described for **1a**, from compound **2a** (0.10 g, 0.411 mmol), 3,4-dichlorobenzaldehyde (0.108 g, 0.616 mmol), dry DMF (1 mL) and a 1M $\text{KO}^t\text{Bu}/^t\text{BuOH}$ solution (0.45 mL, 0.45 mmol).

Data for (Z)-1f. Yield 0.101 g, 62%; yellow solid (after chromatography eluting with 1:6 EtOAc/petroleum ether); mp 228-230 $^\circ\text{C}$; IR (KBr) ν : 1688.7 (CO) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 8.27 (d, 1H, $J = 7.8$ Hz, H-7), 7.81-7.68 (m, 2H, H-9,10), 7.52-7.44 (m, 3H, H-8,2',5'), 7.38 (s, 1H, H α), 7.20 (d, 1H, $J = 7.5$ Hz, H-6'), 5.67 (q, 1H, $J = 7.0$ Hz, H-4), 2.98 (s, 3H, NCH_3), 1.63 (d, 3H, $J = 7.0$ Hz, $\text{C}_4\text{-CH}_3$); $^{13}\text{C-NMR}$ (CDCl_3) δ 167.9 (C-3), 159.8 (C-6), 147.5 (C-11a), 147.2 (C-10a), 136.4 (C-1'), 134.8 (C-3'), 133.3 (C-9), 133.0 (C-4'), 132.9 (C-1), 130.8 (C-5'), 130.5 (C-2'), 128.2 (C-6'), 127.4 (C-7), 127.3 (C-8), 126.8 (C-10), 120.2 (C-6a), 119.3 (C α), 52.0 (C-4), 31.4 (NCH_3), 17.9 ($\text{C}_4\text{-CH}_3$). Anal. Calc. for $\text{C}_{20}\text{H}_{15}\text{Cl}_2\text{N}_3\text{O}_2$: C, 60.01; H, 3.78; N, 10.50. Found: C, 59.87; H, 3.74; N, 10.52.

Data for (E)-1f. Yield 0.098 g, 23%; yellow solid (after chromatography eluting with 1:6 EtOAc/petroleum ether); mp 179-181 $^\circ\text{C}$; IR (KBr) ν : 1686.1 (CO) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 8.26 (d, 1H, $J = 7.9$ Hz, H-7), 7.73-7.64 (m, 2H, H-9,10), 7.48 (t, 1H, $J = 7.9$ Hz, H-8), 7.34-7.29 (m, 2H, H-2',5'), 6.57 (s, 1H, H α), 7.17 (d, 1H, $J = 7.6$ Hz, H-6'), 4.09 (q, 1H, $J = 7.1$ Hz, H-4), 3.39 (s, 3H, NCH_3), 1.62 (d, 3H, $J = 7.1$ Hz, $\text{C}_4\text{-CH}_3$); $^{13}\text{C-NMR}$ (CDCl_3) δ 166.8 (C-3), 159.7 (C-6), 146.7 (C-11a), 144.4 (C-10a), 134.8 (C-1'), 134.1 (C-9), 132.3 (C-3'), 131.9 (C-1), 131.8 (C-4'), 131.6 (C-5'), 129.0 (C-2'), 129.6 (C-6'), 127.9 (C-7), 127.6 (C-8), 126.8 (C-10), 120.6 (C-6a), 112.0 (C α), 51.7 (C-4), 31.9 (NCH_3), 18.4 ($\text{C}_4\text{-CH}_3$). Anal. Calc. for $\text{C}_{20}\text{H}_{15}\text{Cl}_2\text{N}_3\text{O}_2$: C, 60.01; H, 3.78; N, 10.50. Found: C, 59.84; H, 3.83; N, 10.55.

(4*S*,1*Z*)-1-(2,4-Difluorobenzylidene)-2,4-dihydro-2,4-dimethyl-1*H*-pyrazino[2,1-

***b*]quinazoline-3,6-dione (1g).** Obtained as described for **1a**, from compound **2a** (0.111 g, 0.451 mmol), 2,4-difluorobenzaldehyde (0.074 g, 0.676 mmol), dry DMF (1 mL) and a 1M $\text{KO}^t\text{Bu}/^t\text{BuOH}$ solution (0.5 mL, 0.5 mmol). Yield 0.144 g, 87%; white solid (after chromatography eluting with 1:4 EtOAc/petroleum ether); mp 230-232 $^\circ\text{C}$; IR (KBr) ν : 1691.8 (CO) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 8.29 (d, 1H, $J = 8.0$ Hz, H-7), 7.79-7.71 (m, 2H, H-9,10), 7.49 (t, 1H, $J = 8.1$ Hz, H-8), 7.40-7.32 (m, 2H, H-3', H α), 7.00-6.98 (m, 2H, H-5',6'), 5.68 (q, 1H, $J = 7.1$ Hz, H-4), 2.94 (s, 3H, NCH_3), 1.62 (d, 3H, $J = 7.1$ Hz, $\text{C}_4\text{-CH}_3$); $^{13}\text{C-NMR}$ (CDCl_3) δ 167.5 (C-3), 163.4 (dd, $J = 253.6$ and 12.3 Hz, C-3'), 160.4 (dd, $J = 254.2$ and 12.4 Hz, C-4'), 159.9 (C-6), 158.7 (C-11a), 147.4 (C-10a), 135.0 (C-9), 131.7 (C-1), 131.4 (dd, $J = 8.9$ and 8.7 Hz, C-6'), 127.7 (C-7), 127.5 (C-8), 127.0 (C-10), 120.7 (C-6a), 118.1 (dd, $J = 18.9$ and 7.9 Hz, C-1'), 114.0 (C α), 112.1 (dd, $J = 19.6$ and 5.6 Hz, C-5'), 104.6 (t, $J = 25.5$ Hz, C-2'), 52.0 (C-4), 31.5

(NCH₃), 17.6 (C₄-CH₃). Anal. Calc. for C₂₀H₁₅F₂N₃O₂: C, 65.39; H, 4.12; N, 11.44. Found: C, 65.50; H, 4.15; N, 11.49.

(4S,1Z)- and (4S,1E)-1-[(1-Benzyl-3-indolyl)methylene]-2,4-dihydro-2,4-dimethyl-1H-pyrazino[2,1-b]quinazoline-3,6-dione, (Z)-1h and (E)-1h. Obtained as described for **1a**, from compound **2a** (0.30 g, 1.234 mmol), 1-benzylindol-3-carbaldehyde (0.435 g, 1.851 mmol), dry DMF (3 mL) and a 1M KO^tBu/^tBuOH solution (1.3 mL, 1.3 mmol).

Data for (Z)-1h. Yield 0.300 g, 53% as a pale yellow solid (after chromatography eluting with 1:8 EtOAc/petroleum ether); mp 108-110 °C; IR (KBr) ν : 1680.7 (CO) cm⁻¹; ¹H-NMR (DMSO-*d*₆) δ 8.27 (d, 1H, *J* = 8.1 Hz, H-7), 7.84-7.76 (m, 3H, H-9,10,7'), 7.49 (t, 1H, *J* = 8.1 Hz, H-8), 7.40-4.14 (m, 10H, H-2',4',5',6', Ph, H α), 5.71 (q, 1H, *J* = 7.1 Hz, H-4), 5.37 (s, 2H, CH₂Ph), 3.10 (s, 3H, NCH₃), 1.63 (d, 3H, *J* = 7.1 Hz, C₄-CH₃); ¹³C-NMR (DMSO-*d*₆) δ 168.1 (C-3), 160.0 (C-6), 151.0 (C-11a), 147.1 (C-10a), 136.3 (C-7a'), 134.6 (C-9), 131.7, 130.2, 128.0, 126.9 (Ph), 129.0 (C-2'), 127.6 (C-1), 127.6 (C-3a'), 127.2 (C-7), 126.8 (C-8), 126.7 (C-10), 126.6 (C-4'), 123.1 (C-5'), 121.3 (C-6'), 120.7 (C-6a), 119.7 (C α), 110.3 (C-7'), 110.2 (C-3'), 52.0 (C-4), 50.5 (CH₂Ph), 33.8 (NCH₃), 17.1 (C₄-CH₃). Anal. Calc. for C₂₉H₂₄N₄O₂: C, 75.63; H, 5.25; N, 12.17. Found: C, 75.56; H, 5.28; N, 12.13.

Compound **(E)-1h** could not be isolated and its spectral data were obtained from the isomer mixture: ¹H-NMR (DMSO-*d*₆) δ 8.55 (s, 1H, H-2'), 8.28 (d, 1H, *J* = 7.9 Hz, H-7), 7.77-7.12 (m, 12H, H-8,9,10,4',5',6',7',Ph), 7.03 (s, 1H, H α), 5.64 (q, 1H, *J* = 7.1 Hz, H-4), 5.36 (s, 2H, CH₂Ph), 3.50 (s, 3H, NCH₃), 1.55 (d, 3H, *J* = 7.1 Hz, C₄-CH₃).

(4S,1Z)- and (4S,1E)-2,4-Dihydro-2,4-dimethyl-1-[(1-tosyl-3-indolyl)methylene]-1H-pyrazino[2,1-b]quinazoline-3,6-dione, (Z)-1i and (E)-1i. Obtained as described for **1a**, from compound **2a** (0.30 g, 1.234 mmol), 1-tosylindol-3-carbaldehyde (0.551 g, 1.851 mmol), dry DMF (3 mL) and a 1M KO^tBu/^tBuOH solution (1.3 mL, 1.3 mmol).

Data for (Z)-1i. Yield 0.227 g, 36%; red solid (after chromatography eluting with 1:8 EtOAc/petroleum ether); mp 200-202 °C; IR (KBr) ν 1689.4 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 8.09 (d, 1H, *J* = 8.0 Hz, H-7), 7.83 (d, 1H, *J* = 8.0 Hz, H-7'), 7.66-7.53 (m, 2H, H-9,10), 7.61 (d, 2H, *J* = 8.0 Hz, H-2'',6''), 7.46 (d, 1H, *J* = 8.0 Hz, H-4'), 7.43 (s, 1H, H-2'), 7.37 (m, 1H, H α), 7.31 (t, 1H, *J* = 8.0 Hz, H-8), 7.13 (t, 1H, *J* = 8.0 Hz, H-5'), 7.21 (t, 1H, *J* = 8.0 Hz, H-6'), 7.05 (d, 2H, *J* = 8.0 Hz, H-3'',5''), 5.50 (q, 1H, *J* = 7.0 Hz, H-4), 2.74 (s, 3H, NCH₃), 2.14 (s, 3H, C₆H₄CH₃), 1.49 (d, 3H, *J* = 7.0 Hz, C₄-CH₃); ¹³C-NMR (CDCl₃) δ 168.1 (C-3), 160.3 (C-6), 148.0 (C-11a), 146.1 (C-10a), 135.3 (C-9), 135.1 (C-7'a,4''), 132.1 (C-1''), 130.5 (C-2'',6''), 129.9 (C-1), 129.5 (C-2'), 127.9 (C-3'a), 127.6 (C-7), 127.3 (C-3'',5''), 126.7 (C-8), 126.1 (C-10), 124.6 (C-4',5'), 120.6 (C-6a), 120.4 (C-6'), 116.0 (C-3'), 114.2 (C-7'), 113.4 (C α), 52.4 (C-4), 34.5 (NCH₃), 22.0 (C₆H₄CH₃), 18.1 (C₄-CH₃). Anal. Calc. for C₂₉H₂₄N₄O₄S: C, 66.40; H, 4.61; N, 10.68. Found: C, 66.31; H, 4.63; N, 10.65.

Data for (E)-1i. Yield 0.103 g, 16%; orange oil (after chromatography eluting with 1:8 EtOAc/petroleum ether); IR (NaCl) ν : 1686.4 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 8.15 (d, 1H, *J* = 7.8 Hz, H-7), 7.82 (d, 1H, *J* = 7.8 Hz, H-7'), 7.70-7.66 (m, 2H, H-9,10), 7.65 (d, 2H, *J* = 7.5 Hz, H-2'',6''), 7.43-7.34 (m, 2H, H-8,4'), 7.09 (s, 1H, H-2'), 6.62 (m, 1H, H α), 7.21-7.12 (m, 2H, H-

5',6'), 7.02 (d, 2H, $J = 7.5$ Hz, H-3'',5''), 5.50 (q, 1H, $J = 7.1$ Hz, H-4), 3.32 (s, 3H, NCH₃), 2.18 (s, 3H, C₆H₄CH₃), 1.39 (d, 3H, $J = 7.1$ Hz, C₄-CH₃); ¹³C-NMR (CDCl₃) δ 167.3 (C-3), 160.1 (C-6), 147.1 (C-11a), 145.7 (C-10a), 135.5 (C-7'a,4''), 134.6 (C-9), 131.6 (C-1''), 131.0 (C-1), 130.4 (C-2'',6''), 129.6 (C-2',3'a), 128.3 (C-7), 127.7 (C-8,10), 127.4 (C-3'',5''), 125.6 (C-4'), 123.9 (C-5'), 120.9 (C-6a,6'), 119.0 (C-3'), 114.1 (C-7'), 113.4 (C α), 52.1 (C-4), 33.3 (NCH₃), 22.0 (C₆H₄CH₃), 18.2 (C₄-CH₃). Anal. Calc. for C₂₉H₂₄N₄O₄S: C, 66.40; H, 4.61; N, 10.68. Found: C, 66.38; H, 4.58; N, 10.69.

Reaction of (2a) with 4-methoxybenzaldehyde. This reaction was carried out as described for the preparation of **1a**, from compound **2a** (0.10 g, 0.411 mmol), 4-methoxybenzaldehyde (0.074 mL, 0.616 mmol), dry DMF (1 mL) and a 1M KO^tBu/^tBuOH solution (1.0 mL, 1.0 mmol), and after chromatography eluting with 1:6 EtOAc/petroleum ether, compounds (4*S*,1*Z*)- and (4*S*,1*E*)-2,4-dihydro-1-(4-methoxybenzylidene)-2,4-dimethyl-1*H*-pyrazino[2,1-*b*]quinazoline-3,6-dione (**(Z)**-**1j**, **(E)**-**1j**, (4*S*,1*Z*)- and (4*S*,1*E*)-2,4-dihydro-1-(4-methoxybenzylidene)-2-[2-(4-methoxyphenyl)-2-oxoethyl]-4-methyl-1*H*-pyrazino[2,1-*b*]quinazoline-3,6-dione (**(Z)**-**5**, and **(E)**-**5** were obtained. When 1 equivalent of base was used, the reaction only yielded 63% of **(Z)**-**1j**, traces of **(E)**-**1j** together with recovered starting material.

Compound (Z)-1j. Yield 0.093 g, 63%; yellow solid (after chromatography eluting with 1:6 EtOAc/petroleum ether); mp 173-175 °C; IR (KBr) ν 1684.1 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 8.26 (d, 1H, $J = 8.1$ Hz, H-7), 7.79-7.71 (m, 2H, H-9,10), 7.46 (t, 1H, $J = 8.1$ Hz, H-8), 7.32 (d, 2H, $J = 7.8$ Hz, H-2',6'), 7.40 (s, 1H, H α), 6.92 (d, 2H, $J = 7.8$ Hz, H-3',5'), 5.67 (q, 1H, $J = 7.1$ Hz, H-4), 3.82 (s, 3H, OCH₃), 3.00 (s, 3H, NCH₃), 1.61 (d, 3H, $J = 7.1$ Hz, C₄-CH₃); ¹³C-NMR (CDCl₃) δ 168.1 (C-3), 160.2 (C-6), 160.0 (C-4'), 148.2 (C-11a), 147.7 (C-10a), 134.9 (C-9), 131.1 (C-2',6'), 129.6 (C-1'), 127.4 (C-7), 127.1 (C-8), 127.0 (C-10), 125.5 (C-1), 123.0 (C α), 120.3 (C-6a), 114.3 (C-3',5'), 55.5 (OCH₃), 51.1 (C-4), 34.9 (NCH₃), 17.5 (C₄-CH₃). Anal. Calc. for C₂₁H₁₉N₃O₃: C, 69.79; H, 5.30; N, 11.63. Found: C, 69.83; H, 5.33; N, 11.60.

Compound (E)-1j. Yield 0.023g, 16%; yellow solid (after chromatography eluting with 1:6 EtOAc/petroleum ether); mp 208-210 °C; IR (KBr) ν 1684.0 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 8.28 (d, 1H, $J = 8.0$ Hz, H-7), 7.68 (t, 1H, $J = 7.9$ Hz, H-9), 7.48 (t, 1H, $J = 7.9$ Hz, H-8), 7.40 (d, 1H, $J = 8.0$ Hz, H-10), 7.39 (d, 2H, $J = 7.8$ Hz, H-2',6'), 6.79 (d, 2H, $J = 7.8$ Hz, H-3',5'), 6.66 (s, 1H, H α), 5.62 (q, 1H, $J = 7.1$ Hz, H-4), 3.80 (s, 3H, OCH₃), 3.39 (s, 3H, NCH₃), 1.64 (d, 3H, $J = 7.1$ Hz, C₄-CH₃); ¹³C-NMR (CDCl₃) δ 167.0 (C-3), 159.9 (C-6), 158.9 (C-4'), 147.1 (C-11a), 145.8 (C-10a), 134.8 (C-9), 131.7 (C-2',6'), 127.8 (C-7), 127.7 (C-8), 126.9 (C-10), 126.0 (C-1',1''), 123.5 (C-6a), 120.8 (C α), 113.6 (C-3',5'), 55.4 (OCH₃), 51.9 (C-4), 31.9 (NCH₃), 18.0 (C₄-CH₃). Anal. Calc. for C₂₁H₁₉N₃O₃: C, 69.79; H, 5.30; N, 11.63. Found: C, 69.67; H, 5.34; N, 11.64.

Compound (Z)-5. Yield 0.025 g, 12%; orange solid (after chromatography eluting with 1:6 EtOAc/petroleum ether); mp 96-98 °C; IR (KBr) ν 1682.2 and 1602.8 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ : 8.30 (d, 1H, $J = 7.9$ Hz, H-7), 7.80-7.72 (m, 2H, H-8,9), 7.63 (d, 2H, $J = 7.4$ Hz, H-2',6'), 7.55-7.45 (m, 1H, H-10), 7.47 (d, 2H, $J = 7.4$ Hz, H-3',5'), 7.37 (s, 1H, H α), 6.96 (d, 2H, $J = 7.3$ Hz, H-3'',5''), 6.79 (d, 2H, $J = 7.3$ Hz, H-2'',6''), 5.77 (q, 1H, $J = 7.1$ Hz, H-4), 5.54 (d, 1H,

$J = 17.4$ Hz, NCH_2), 4.41 (d, 1H, $J = 17.4$ Hz, NCH_2), 3.87 and 3.83 (s, 6H, OCH_3), 1.67 (d, 3H, $J = 7.1$ Hz, $\text{C}_4\text{-CH}_3$); ^{13}C -NMR (CDCl_3) δ 189.8 (COCH_2), 169.1 (C-3), 163.8 (C-6), 160.2 and 160.0 (C-4',4''), 148.2 (C-11a), 147.8 (C-10a), 134.5 (C-9), 130.9 and 130.1 (C-2',2'',6',6''), 127.4 (C-7), 128.9 and 127.9 (C-1',1''), 127.8 (C-8), 126.7 (C-10), 125.1 (C-1), 123.1 (C-6a), 120.3 (C α), 114.3 and 113.7 (C-3',3'',5',5''), 55.3 and 55.3 (2 OCH_3), 55.2 (C-4), 55.9 (COCH_2), 17.1 ($\text{C}_4\text{-CH}_3$). Anal. Calc. for $\text{C}_{29}\text{H}_{25}\text{N}_3\text{O}_5$: C, 70.29; H, 5.09; N, 8.48. Found: C, 70.19; H, 5.06; N, 8.42.

Compound (E)-5. Yield 0.016 g, 8%; orange solid (after chromatography eluting with 1:6 EtOAc/petroleum ether); mp 94-96 °C; IR (KBr) ν : 1681.7 and 1601.6 (CO) cm^{-1} ; ^1H -NMR (CDCl_3) δ 8.29 (d, 1H, $J = 8.0$ Hz, H-7), 7.99 (d, 2H, $J = 7.3$ Hz, H-2',6'), 7.67 (d, 1H, $J = 7.9$ Hz, H-9), 7.48 (t, 1H, $J = 7.9$ Hz, H-8), 7.39 (d, 1H, $J = 7.9$ Hz, H-10), 7.32 (d, 2H, $J = 7.3$ Hz, H-3',5'), 6.97 (d, 2H, $J = 7.3$ Hz, H-3'',5''), 6.74 (d, 2H, $J = 7.3$ Hz, H-2'',6''), 6.41 (s, 1H, H α), 5.68 (q, 1H, $J = 7.1$ Hz, H-4), 5.55 (d, 1H, $J = 17.5$ Hz, NCH_2), 4.87 (d, 1H, $J = 17.5$ Hz, NCH_2), 3.87 and 3.83 (s, 6H, OCH_3), 1.67 (d, 3H, $J = 7.1$ Hz, $\text{C}_4\text{-CH}_3$); ^{13}C -NMR (CDCl_3) δ 189.8 (COCH_2), 167.1 (C-3), 164.1 (C-6), 159.8 and 159.6 (C-4',4''), 146.9 (C-11a), 145.6 (C-10a), 134.5 (C-9), 131.4 and 130.5 (C-2',2'',6',6''), 127.6 (C-7), 127.5 (C-8), 126.7 (C-10), 128.6 and 127.2 (C-1',1''), 125.6 (C-1), 123.6 (C α), 120.6 (C-6a), 114.0 and 113.2 (C-3',3'',5',5''), 57.5 and 55.1 (2 OCH_3), 51.9 (C-4), 51.7 (COCH_2), 17.5 ($\text{C}_4\text{-CH}_3$). Anal. Calc. for $\text{C}_{29}\text{H}_{25}\text{N}_3\text{O}_5$: C, 70.29; H, 5.09; N, 8.48. Found: C, 70.15; H, 5.03; N, 8.51.

(4S,1Z)-1-(4-Chlorobenzylidene)-2,4-dihydro-4-methyl-1H-pyrazino[2,1-b]quinazoline-3,6-dione (1k). To a solution of (4S)-2-acetyl-1,2,3,4-tetrahydro-4-methyl-5H-pyrazino[2,1-b]quinazoline-3,6-dione^{3b} (0.148 g, 0.546 mmol) and 4-chlorobenzaldehyde (0.115 g, 0.819 mmol) in dry DMF (1 mL) at 0 °C and under an argon atmosphere, was added dropwise a 1M $\text{KO}^t\text{Bu}/^t\text{BuOH}$ solution (0.573 mL, 0.573 mmol). The mixture was stirred at rt for 16 h. Then, the reaction was neutralized with acetic acid, poured onto ice, and the yellow solid that precipitated was collected by filtration and identified as **1k**. Yield 0.180 g, 94%; mp 173-175 °C; $[\alpha]_{\text{D}}^{25} = -471.6$ (c 0.03, CHCl_3); IR (KBr) ν 1687.1 (CO) cm^{-1} ; ^1H -NMR (CDCl_3) δ 8.28 (d, 1H, $J = 8.1$ Hz, H-7), 7.82-7.75 (m, 3H, H-9,10,NH), 7.51 (t, 1H, $J = 8.1$ Hz, H-8), 7.48-7.38 (m, 4H, H-2',3',5',6'), 7.47 (s, 1H, H α), 5.57 (q, 1H, $J = 7.2$ Hz, H-4), 1.65 (d, 3H, $J = 7.2$ Hz, $\text{C}_4\text{-CH}_3$); ^{13}C -NMR (CDCl_3) δ 166.1 (C-3), 160.0 (C-6), 151.0 (C-11a), 146.9 (C-10a), 134.8 (C-9), 134.6 (C-1'), 131.5 (C-4'), 129.8 (C-2',6'), 129.6 (C-3',5'), 127.5 (C-7), 127.3 (C-8), 126.8 (C-10), 126.3 (C-1), 120.2 (C-6a), 114.6 (C α), 51.6 (C-4), 19.3 ($\text{C}_4\text{-CH}_3$). Anal. Calc. for $\text{C}_{19}\text{H}_{14}\text{ClN}_3\text{O}_2$: C, 64.87; H, 4.01; N, 11.94. Found: C, 64.83; H, 4.05; N, 11.90.

(3S)-4-Acetyl-1,3-dimethylpiperazine-2,5-dione (13). A solution of (3S)-1,3-dimethylpiperazine-2,5-dione (0.5 g, 3.52 mmol) in acetic anhydride (10 mL) was refluxed at 140 °C for 7 h with exclusion of the moisture. The excess of anhydride was evaporated under reduced pressure yielding compound **13** as a yellow oil. Yield 0.636 g, 98%; $[\alpha]_{\text{D}}^{25} = -24$ (c 0.05, CHCl_3); IR (NaCl) ν 1709.5 and 1672.3 (CO) cm^{-1} ; ^1H -NMR (CDCl_3) δ 5.03 (q, 1H, $J = 7.2$ Hz, H-3), 4.24 (d, 1H, $J = 18.3$ Hz, H-6), 3.94 (d, 1H, $J = 18.3$ Hz, H-6), 2.98 (s, 3H, NCH_3), 2.52 (s, 3H, COCH_3), 1.43 (d, 3H, $J = 7.2$ Hz, $\text{C}_3\text{-CH}_3$); ^{13}C -NMR (CDCl_3) δ 171.0 (N_1COCH_3),

167.6 (C-2), 166.5 (C-5), 52.6 (C-3), 52.9 (C-6), 33.3 (NCH₃), 27.1 (COCH₃), 18.0 (C₃-CH₃). Anal. Calc. for C₈H₁₂N₂O₃: C, 52.17; H, 6.57; N, 15.21. Found: C, 51.94; H, 6.55; N, 15.26.

(6S,3Z)- and (6S, 3E)-4-Acetyl-3-(4-chlorobenzylidene)-4,6-dimethylpiperazine-2,5-dione, (Z)-14 and (E)-14. Obtained as described for **1a**, from compound **13** (0.100 g, 0.550 mmol), 4-chlorobenzaldehyde (0.100 mL, 0.714 mmol), dry DMF (1 mL) and a 1M KO^tBu/^tBuOH solution (0.6 mL, 0.6 mmol).

Compound (Z)-14. Yield 0.019 g, 11%; yellow solid (after chromatography eluting with 1:8 Cl₂CH₂/petroleum ether); mp 129-131 °C; [α]_D²⁵ = - 158.4 (c 0.25, CHCl₃); IR (KBr) ν: 1703.6 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 7.39 (d, 2H, *J* = 8.0 Hz, H-2',6'), 7.23 (s, 1H, Hα), 7.21 (d, 2H, *J* = 8.0 Hz, H-3',5'), 5.21 (q, 1H, *J* = 7.1 Hz, H-6), 2.86 (s, 3H, NCH₃), 2.58 (s, 3H, COCH₃), 1.49 (d, 3H, *J* = 7.1 Hz, C₆-CH₃); ¹³C-NMR (CDCl₃) δ 171.6 (C=O), 168.2 (C-5), 163.3 (C-2), 134.5 (C-4'), 130.8 (C-2',6'), 123.1 (C-3), 131.9 (C-1'), 131.3 (Cα), 129.1 (C-3',5'), 52.8 (C-6), 34.8 (NCH₃), 27.2 (COCH₃), 18.4 (C₆-CH₃). Anal. Calc. for C₁₅H₁₅ClN₂O₃: C, 58.73; H, 4.93; N, 9.13. Found: C, 58.93; H, 5.06; N, 9.09.

Compound (E)-14. Yield 0.006 g, 4%; yellow solid (after chromatography eluting with 1:8 Cl₂CH₂/petroleum ether); [α]_D²⁵ = - 52.8 (c 0.25, CHCl₃); IR (KBr) ν 1693.3 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 7.41-7.13 (m, 4H, H-2',3',5',6'), 6.59 (s, 1H, Hα), 5.18 (q, 1H, *J* = 7.1 Hz, H-6), 3.28 (s, 3H, NCH₃), 2.49 (s, 3H, COCH₃), 1.50 (d, 3H, *J* = 7.1 Hz, C₆-CH₃). Anal. Calc. for C₁₅H₁₅ClN₂O₃: C, 58.73; H, 4.93; N, 9.13. Found: C, 58.89; H, 5.00; N, 9.10.

General procedure for the catalytic hydrogenation of compounds (1)

A suspension of the suitable compound **1** and 10% Pd-C in EtOH was hydrogenated at 40 psi for 6 h. After filtering off the Pd-C through a layer of celite, the solvent was evaporated and the residue was purified by fast chromatography on silica gel, eluting with a 1:6 ethyl acetate-petroleum ether mixture.

(4S,1S)-1-(4-Chlorobenzyl)-2,4-dihydro-2,4-dimethyl-1H-pyrazino[2,1-*b*]quinazoline-3,6-dione (3a) and (4S, 1S)-1-(4-chlorobenzyl)-2,4,7,8,9,10-hexahydro-2,4-dimethyl-1H-pyrazino[2,1-*b*]quinazoline-3,6-dione (15a). Obtained following the general procedure from **1a** (0.100 g, 0.273 mmol) and 10% Pd-C (0.016 g) in EtOH (10 mL).

Compound (3a). Yield 0.063 g, 63%; yellow solid; mp 96-98 °C; IR (KBr) ν 1668.0 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 8.26 (d, 1H, *J* = 8.0 Hz, H-7), 7.78 (t, 1H, *J* = 7.9 Hz, H-9), 7.65 (d, 1H, *J* = 8.0 Hz, H-10), 7.49 (t, 1H, *J* = 7.9 Hz, H-8), 7.25 (d, 2H, *J* = 7.4 Hz, H-2',6'), 7.09 (d, 2H, *J* = 7.4 Hz, H-3',5'), 5.16 (q, 1H, *J* = 7.1 Hz, H-4), 4.79 (dd, 1H, *J* = 1.4 and *J* = 13.1 Hz, H-1), 3.42-3.33 (m, 2H, Hα), 2.81 (s, 3H, NCH₃), 1.14 (d, 3H, *J* = 7.1 Hz, C₄-CH₃); ¹³C-NMR (CDCl₃) δ 167.2 (C-3), 160.4 (C-6), 150.3 (C-11a), 147.3 (C-10a), 135.4 (C-1'), 134.9 (C-9), 129.9 (C-2',6'), 129.3 (C-3',5'), 127.9 (C-4'), 127.2 (C-7), 127.0 (C-8), 126.9 (C-10), 120.3 (C-6a), 65.2 (C-1), 52.4 (C-4), 41.6 (Cα), 34.1 (NCH₃), 18.4 (C₄-CH₃). Anal. Calc. for C₂₀H₁₈ClN₃O₂: C, 65.31; H, 4.93; N, 11.42. Found: C, 65.48; H, 4.96; N, 10.43.

Compound (15a). Yield 0.017 g, 17%; yellow solid; mp 94-96 °C; IR (KBr) ν 1663.7 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 7.25 (d, 2H, *J* = 7.4 Hz, H-2',6'), 7.04 (d, 2H, *J* = 7.4 Hz, H-3',5'), 4.99 (q,

1H, $J = 7.1$ Hz, H-4), 4.65-4.61 (m, 1H, H-1), 3.32-3.27 (m, 2H, H α), 2.84 (s, 3H, NCH₃), 2.60-2.49 (m, 4H, H-7,10), 1.80-1.68 (m, 4H, H-8,9), 1.07 (d, 3H, $J = 7.1$ Hz, C₄-CH₃); ¹³C-NMR (CDCl₃) δ 167.2 (C-3), 160.5 (C-6), 159.5 (C-11a), 151.2 (C-10a), 135.3 (C-1'), 129.8 (C-2',6'), 129.3 (C-3',5'), 127.9 (C-4'), 120.1 (C-6a), 64.4 (C-1), 51.9 (C-4), 41.2 (C α), 33.7 (NCH₃), 31.2 (C-9), 22.5 (C-7), 21.9 (C-8), 21.5 (C-10), 18.1 (C₄-CH₃). Anal. Calc. for C₂₀H₂₂ClN₃O₂: C, 64.60; H, 5.96; N, 11.30. Found: C, 64.53; H, 5.98; N, 11.33.

(4S,1S)-1-(4-Chlorobenzyl)-2,4-dihydro-4-methyl-2-phenetyl-1H-pyrazino[2,1-*b*]quinazoline-3,6-dione (3c) and (4S,1S)-1-(4-chlorobenzyl)-2,4,7,8,9,10-hexahydro-4-methyl-2-phenetyl-1H-pyrazino[2,1-*b*]quinazoline-3,6-dione (15c). Obtained following the general procedure from **1c** (0.027 g, 0.059 mmol) and 10% Pd-C (0.003 g) in EtOH (1 mL).

Compound (3c). Yield, 0.014 (51%), as a colorless oil; IR (KBr) ν 1669.3 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 8.30 (d, 1H, $J = 8.0$ Hz, H-7), 7.80 (t, 1H, $J = 7.9$ Hz, H-9), 7.64 (d, 1H, $J = 7.9$ Hz, H-10), 7.52 (t, 1H, $J = 8.0$ Hz, H-8), 7.15-7.04 (m, 4H, H-2',3',5',6'), 7.30 (m, 5H, CH₂CH₂Ph), 5.21 (q, 1H, $J = 7.1$ Hz, H-4), 4.60-4.51 (m, 1H, H-1), 4.25-4.14 (m, 1H, CH₂CH₂Ph), 3.38-3.22 (m, 2H, H α), 2.84-2.78 (m, 1H, CH₂CH₂Ph), 2.65-2.62 (m, 2H, CH₂CH₂Ph), 1.32 (d, 3H, $J = 7.1$ Hz, C₄-CH₃); ¹³C-NMR (CDCl₃) δ 165.8 (C-3), 159.0 (C-6), 149.6 (C-11a), 146.0 (C-10a), 134.2 (C-9), 136.7 (C-1'), 133.6 (C-4'), 129.4 and 129.1 (C-2',3',5',6'), 128.5 and 127.9 (C-2'',3'',5'',6''), 127.4 (C-1''), 127.4 (C-7), 126.6 (C-8), 126.3 (C-4''), 125.9 (C-10), 119.0 (C-6a), 62.2 (C-1), 51.2 (C-4), 40.9 (C α), 46.7 (CH₂CH₂Ph), 32.0 (CH₂CH₂Ph), 17.0 (C₄-CH₃) ppm. Anal. Calc. for C₂₇H₂₄ClN₃O₂: C, 70.81; H, 5.28; N, 9.18. Found: C, 70.65; H, 5.01; N, 8.98.

Compound (15c). Yield, 0.021 g (44%); colorless oil; IR (KBr) ν 1663.6 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 7.30-7.02 (m, 9H, H-2',3',5',6',Ph), 5.07 (q, 1H, $J = 7.1$ Hz, H-4), 4.44-4.39 (m, 1H, H-1), 4.20-4.09 (m, 1H, CH₂CH₂Ph), 3.25-3.11 (m, 2H, H α), 2.81-2.74 (m, 1H, CH₂CH₂Ph), 2.60-2.49 (m, 6H, CH₂CH₂Ph, H-7,10), 1.84-1.74 (m, 4H, H-8,9), 1.24 (d, 3H, $J = 7.1$ Hz, C₄-CH₃); ¹³C-NMR (CDCl₃) δ 166.9 (C-3), 160.4 (C-6), 159.7 (C-11a); 141.1 (C-10a), 137.9 (C-1''), 135.2 (C-1'), 129.6 and 129.0 (C-2',3',5',6'); 128.6 and 128.5 (C-2'',3'',5'',6''), 127.7 (C-4'); 126.5 (C-4''); 119.9 (C-6a), 62.9 (C-1), 52.1 (C-4), 41.9 (C α), 47.7 (CH₂CH₂Ph), 33.1 (CH₂CH₂Ph), 31.7 (C-9), 22.2 (C-7), 22.0 (C-8), 21.6 (C-10), 18.0 (C₄-CH₃) ppm. Anal. Calcd. for C₂₇H₂₈ClN₃O₂: C, 70.19; H, 6.11; N, 9.10. Found: C, 69.90; H, 5.92; N, 8.98.

(4S,1S)-1-(4-Bromobenzyl)-2,4-dihydro-2,4-dimethyl-1H-pyrazino[2,1-*b*]quinazoline-3,6-dione (3d). Obtained following the general procedure from **1d** (0.100 g, 0.243 mmol) and 10% Pd-C (0.014 g) in EtOH (10 mL). Yield 0.055 g, 56%; reddish solid; mp 140-142 °C; IR (KBr) ν 1720.2 and 1666.1 (CO) cm⁻¹; ¹H-NMR (DMSO-*d*₆) δ 8.11 (d, 1H, $J = 8.0$ Hz, H-7), 7.96 (t, 1H, $J = 7.9$ Hz, H-9), 7.68 (d, 1H, $J = 8.0$ Hz, H-10), 7.54 (t, 1H, $J = 7.9$ Hz, H-8), 7.23 (d, 2H, $J = 7.3$ Hz, H-2',6'), 7.02 (d, 2H, $J = 7.3$ Hz, H-3',5'), 5.03-4.99 (m, 1H, H-1), 4.75 (q, 1H, $J = 7.1$ Hz, H-4), 3.49-3.35 (m, 2H, H α , overlapped with the water signal), 2.93 (s, 3H, NCH₃), 0.75 (d, 3H, $J = 7.1$ Hz, C₄-CH₃) ppm; ¹³C-NMR (DMSO-*d*₆) δ 167.4 (C-3), 161.2 (C-6), 152.3 (C-11a), 148.5 (C-10a), 137.5 (C-1'), 136.4 (C-9), 131.4 (C-2',6'), 130.2 (C-3',5'), 128.8 (C-4'), 128.4 (C-7), 128.5 (C-8), 127.7 (C-10), 121.2 (C-6a), 64.9 (C-1), 53.1 (C-4), 39.7 (C α), 34.2 (NCH₃), 19.1

(C₄-CH₃). Anal. Calc. for C₂₀H₁₈BrN₃O₂: C, 58.26; H, 4.40; N, 10.19. Found: C, 58.36; H, 4.42; N, 10.17.

(4S,1S)-1-(3,4-Dichlorobenzyl)-2,4-dihydro-2,4-dimethyl-1H-pyrazino[2,1-b]quinazoline-3,6-dione (3f). Obtained following the general procedure from **1f** (0.035 g, 0.087 mmol) and 10% Pd-C (0.005 g) in EtOH (2 mL). Yield 0.014 g, 41%; yellow solid; mp 190-192 °C; IR (KBr) ν 1661.1 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 8.29 (d, 1H, *J* = 8.0 Hz, H-7), 7.81 (t, 1H, *J* = 7.9 Hz, H-9), 7.63 (d, 1H, *J* = 8.0 Hz, H-10), 7.52 (t, 1H, *J* = 7.9 Hz, H-8), 7.38 (d, 1H, *J* = 8.0 Hz, H-5'), 7.30 (d, 1H, *J* = 2.0 Hz, H-2'), 7.00 (d, 1H, *J* = 8.0 Hz, H-6'), 5.27 (q, 1H, *J* = 7.1 Hz, H-4), 4.76 (dd, 1H, *J* = 1.9 Hz and *J* = 7.2 Hz, H-1), 3.37-3.25 (m, 2H, H α), 2.92 (s, 3H, NCH₃), 1.46 (d, 3H, *J* = 7.1 Hz, C₄-CH₃); ¹³C-NMR (CDCl₃) δ 167.5 (C-3), 160.6 (C-6), 149.9 (C-11a), 147.3 (C-10a), 136.3 (C-1'), 135.3 (C-9), 133.6 (C-2'), 132.5 (C-3'), 131.8 (C-5'), 131.4 (C-6'), 129.4 (C-4'), 127.7 (C-7), 127.3 (C-8), 127.2 (C-10), 120.6 (C-6a), 65.3 (C-1), 52.6 (C-4), 41.7 (C α), 34.7 (NCH₃), 19.3 (C₄-CH₃). Anal. Calc. for C₂₀H₁₇Cl₂N₃O₂: C, 59.71; H, 4.26; N, 10.45. Found: C, 59.84; H, 4.25; N, 10.48.

(4S,1S)-1-(2,4-Difluorobenzyl)-2,4-dihydro-2,4-dimethyl-1H-pyrazino[2,1-b]quinazoline-3,6-dione (3g). Obtained following the general procedure from **1g** (0.035 g, 0.095 mmol) and 10% Pd-C (0.005 g) in EtOH (2 mL). Yield, 0.011 g, 30% (50% yield based on unrecovered starting material); colourless oil; IR (KBr) ν 1673.9 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 8.28 (d, 1H, *J* = 8.0 Hz, H-7), 7.77 (t, 1H, *J* = 8.0 Hz, H-9), 7.57-7.58 (m, 2H, H-8,10), 7.08 (q, 1H, *J* = 7.6 Hz, H-5'), 6.75-6.85 (m, 2H, H-3',6'), 5.28 (q, 1H, *J* = 7.1 Hz, H-4), 4.76-4.71 (m, 1H, H-1), 3.46-3.29 (m, 2H, H α), 2.98 (s, 3H, NCH₃), 1.54 (d, 3H, *J* = 7.1 Hz, C₄-CH₃); ¹³C-NMR (CDCl₃) δ 165.2 (C-3), 160.8 (dd, *J* = 250.2 and 12.1 Hz, C-2'), 158.4 (C-6), 159.7 (dd, *J* = 249.0 and 11.8 Hz, C-4'), 147.5 (C-11a), 145.0 (C-10a), 132.9 (C-9), 132.7 (dd, *J* = 9.7 and 9.6 Hz, C-6'), 125.4 (C-7), 124.9 (C-8), 124.9 (C-10), 118.3 (C-6a), 116.6 (dd, *J* = 15.9 and 3.9 Hz, C-1'), 110.0 (dd, *J* = 21.2 and 3.7 Hz, C-5'), 102.3 (t, *J* = 25.8 Hz, C-3'), 64.3 (C-1), 52.7 (C-4), 35.1 (C α), 34.3 (NCH₃), 19.1 (C₄-CH₃). Anal. Calc. for C₂₀H₁₇F₂N₃O₂: C, 65.03; H, 4.64; N, 11.38. Found: C, 64.95; H, 4.66; N, 11.40.

(4S,1S)-1-[(1-Benzyl-3-indolyl)methyl]-2,4-dihydro-2,4-dimethyl-1H-pyrazino[2,1-b]quinazoline-3,6-dione (3h). Obtained following the general procedure from **1h** (0.100 g, 0.217 mmol) and 10% Pd-C (0.012 g) in EtOH (10 mL). Yield, 0.056 g, 86%; pale yellow oil; IR (KBr) ν 1665.3 (CO) cm⁻¹; ¹H-NMR (CDCl₃) δ 8.25 (d, 1H, *J* = 7.9 Hz, H-7), 7.81 (t, 1H, *J* = 7.9 Hz, H-9), 7.41 (d, 1H, *J* = 7.9 Hz, H-10), 7.50 (t, 1H, *J* = 7.9 Hz, H-8), 7.33-7.20 (m, 5H, Ph), 7.13-7.06 (m, 2H, H-2',4'), 6.99-6.94 (m, 2H, H-5',6'), 7.72 (d, 1H, *J* = 7.9 Hz, H-7'), 5.24 (s, 2H, CH₂Ph), 5.14 (q, 1H, *J* = 7.1 Hz, H-4), 4.92-4.87 (m, 1H, H-1), 3.60-3.53 (m, 2H, H α), 2.93 (s, 3H, NCH₃), 1.11 (d, 3H, *J* = 7.1 Hz, C₄-CH₃); ¹³C-NMR (CDCl₃) δ 167.5 (C-3), 160.6 (C-6), 151.2 (C-11a), 144.8 (C-10a), 137.4 (C-7a'), 133.8 (C-9), 129.2, 127.4, 127.3, 127.2 (Ph), 128.4 (C-2'), 128.3 (C-7), 128.2 (C-8), 127.9 (C-10), 127.1 (C-4'), 122.7 (C-5'), 120.3 (C-6'), 119.0 (C-6a), 110.4 (C-7'), 110.1 (C-3'), 109.1 (C-3a'), 64.7 (C-1), 52.7 (C-4), 51.2 (CH₂Ph), 32.2 (C α), 34.3 (NCH₃), 18.8 (C₄-CH₃). Anal. Calc. for C₂₉H₂₆N₄O₂: C, 75.30; H, 5.67; N, 12.11. Found: C, 75.41; H, 5.64; N, 12.14.

(4S,1S)-2,4-Dihydro-2,4-dimethyl-1-[(1-tosyl-3-indolyl)methyl]-1H-pyrazino[2,1-b]quinazoline-3,6-dione (3i). Obtained following the general procedure from **1i** (0.080 g, 0.152 mmol) and 10% Pd-C (0.009 g) in EtOH (6 mL). Yield, 0.061 g, 77%; pale yellow oil; IR (KBr) ν 1669.9 (CO) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 8.26 (d, 1H, $J = 8.0$ Hz, H-7), 7.99 (d, 1H, $J = 8.0$ Hz, H-7'), 7.84-7.78 (m, 2H, H-9,10), 7.52 (t, 1H, $J = 7.9$ Hz, H-8), 7.74-7.76 (m, 3H, H-4',2'',6''), 7.44 (s, 1H, H-2'), 7.32 (t, 1H, $J = 7.6$ Hz, H-6'), 7.20 (d, 2H, $J = 7.5$ Hz, H-3'',5''), 7.12 (t, 1H, $J = 7.6$ Hz, H-5'), 5.11 (q, 1H, $J = 7.1$ Hz, H-4), 4.87-4.83 (m, 1H, H-1), 3.48 (m, 2H, H α), 2.84 (s, 3H, NCH $_3$), 2.35 (s, 3H, CH $_3$ -C $_6$ H $_4$), 0.99 (d, 3H, $J = 7.1$ Hz, C $_4$ -CH $_3$); $^{13}\text{C-NMR}$ (CDCl_3) δ 165.7 (C-3), 159.1 (C-6), 149.6 (C-11a), 148.9 (C-4''), 145.9 (C-7'a), 144.1 (C-10a), 133.9 (C-9), 129.0 (C-2'), 128.9 (C-1''), 128.8 (C-2'',6''), 126.2 (C-7), 125.8 (C-8), 125.6 (C-3'',5''), 125.5 (C-10), 126.2 (C-4'), 123.9 (C-5'), 122.4 (C-6'), 119.6 (C-6a), 115.2 (C-7'), 112.7 (C-3'a), 110.0 (C-3'), 63.9 (C-1), 52.4 (C-4), 32.0 (C α), 34.3 (NCH $_3$), 22.0 (CH $_3$ -C $_6$ H $_4$), 18.8 (C $_4$ -CH $_3$). Anal. Calc. for C $_{29}$ H $_{26}$ N $_4$ O $_4$ S: C, 66.14; H, 4.98; N, 10.64. Found: C, 65.95; H, 5.00; N, 10.66.

(4S,1S)-2,4-Dihydro-1-(4-methoxybenzyl)-2,4-dimethyl-1H-pyrazino[2,1-b]quinazoline-3,6-dione (3j) and (4S,1S)-2,4,7,8,9,10-hexahydro-1-(4-methoxybenzyl)-2,4-dimethyl-1H-pyrazino[2,1-b]quinazoline-3,6-dione (15j). Obtained following the general procedure from **1j** (0.107 g, 0.296 mmol) and 10% Pd-C (0.017 g) in EtOH (10 mL), which afforded **3j** + **15j** after 6 h reaction time. Starting from **1j** (0.101 g, 0.279 mmol) and 10% Pd-C (0.016 g) in EtOH (10 mL), **15j** was the only product after 16 h. Yield, 0.051 g, 48% (together with 30% of **15j** after 6 h); yellow oil; IR (KBr) ν 1663.8 (CO) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 8.25 (d, 1H, $J = 8.0$ Hz, H-7), 7.76 (t, 1H, $J = 7.9$ Hz, H-9), 7.64 (d, 1H, $J = 8.0$ Hz, H-10), 7.46 (t, 1H, $J = 7.9$ Hz, H-8), 6.98 (d, 2H, $J = 7.5$ Hz, H-2',6'), 6.77 (d, 2H, $J = 7.5$ Hz, H-3',5'), 5.15 (q, 1H, $J = 7.1$ Hz, H-4), 4.75-4.70 (m, 1H, H-1), 3.72 (s, 3H, OCH $_3$), 3.35-3.31 (m, 2H, H α), 2.88 (s, 3H, NCH $_3$), 1.18 (d, 3H, $J = 7.1$ Hz, C $_4$ -CH $_3$) ppm; $^{13}\text{C-NMR}$ (CDCl_3) δ 167.2 (C-3), 160.4 (C-6), 150.4 (C-4'), 147.3 (C-10a,11a), 134.7 (C-9), 130.6 (C-2',6'), 127.1 (C-1'), 127.0 (C-7), 126.8 (C-8), 126.7 (C-10), 120.1 (C-6a), 114.4 (C-3',5'), 65.2 (C-1), 55.4 (OCH $_3$), 52.4 (C-4), 40.8 (C α), 34.2 (NCH $_3$), 18.4 (C $_4$ -CH $_3$). Anal. Calc. for C $_{21}$ H $_{21}$ N $_3$ O $_3$: C, 69.41; H, 5.82; N, 11.56. Found: C, 69.36; H, 5.79; N, 11.59.

Data for (15j). Yield, 0.085 g, 83%; yellow solid; mp 138-140 $^{\circ}\text{C}$; IR (KBr) ν 1663.1 (CO) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 6.92 (d, 2H, $J = 7.8$ Hz, H-2',6'), 6.77 (d, 2H, $J = 7.8$ Hz, H-3',5'), 4.96 (q, 1H, $J = 7.1$ Hz, H-4), 4.57-4.53 (m, 1H, H-1), 3.23-3.18 (m, 2H, H α), 3.70 (s, 3H, OCH $_3$), 2.85 (s, 3H, NCH $_3$), 2.57-2.45 (m, 4H, H-7,10), 1.78-1.75 (m, 4H, H-8,9), 1.05 (d, 3H, $J = 7.1$ Hz, C $_4$ -CH $_3$); $^{13}\text{C-NMR}$ (CDCl_3) δ 167.1 (C-3), 160.5 (C-6), 151.3 (C-4'), 143.9 (C-11a), 143.8 (C-10a), 130.8 (C-2',6'), 127.3 (C-1'), 120.0 (C-6a), 114.6 (C-3',5'), 64.8 (C-1), 55.4 (OCH $_3$), 52.1 (C-4), 40.7 (C α), 33.9 (NCH $_3$), 31.5 (C-9), 22.4 (C-7), 22.2 (C-8), 21.7 (C-10), 18.3 (C $_4$ -CH $_3$) ppm. Anal. Calc. for C $_{21}$ H $_{25}$ N $_3$ O $_3$: C, 68.64; H, 6.86; N, 11.44. Found: C, 68.53; H, 6.81; N, 11.46.

(4S,1S)-1-(4-Chlorobenzyl)-2,4-dihydro-4-methyl-1H-pyrazino[2,1-b]quinazoline-3,6-dione (3k), (4S,1S)-1-(4-chlorobenzyl)-2,4,7,8,9,10-hexahydro-4-methyl-1H-pyrazino[2,1-b]quinazoline-3,6-dione (15k) and (4S,1R)-1-(4-chlorobenzyl)-2,4-dihydro-4-methyl-1H-pyrazino[2,1-b]quinazoline-3,6-dione (16). Obtained

following the general procedure from **1k** (0.030 g, 0.085 mmol) and 10% Pd-C (0.005 g) in EtOH (2 mL).

Compound (3k). Yield, 0.009 g, 30%; colorless oil; IR (KBr) ν 2930.5 (NH), 1686.8 (CO) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 8.31 (d, 1H, $J = 8.0$ Hz, H-7), 7.81 (t, 1H, $J = 7.9$ Hz, H-9), 7.72 (d, 1H, $J = 8.0$ Hz, H-10), 7.53 (t, 1H, $J = 7.9$ Hz, H-8), 7.38-7.23 (m, 4H, H-2',3',5',6'), 6.46 (br s, 1H, NH), 5.24 (q, 1H, $J = 7.1$ Hz, H-4), 4.86-4.79 (m, 1H, H-1), 3.48 (dd, 1H, $J = 13.4$ and $J = 3.7$ Hz, H α), 3.17 (dd, 1H, $J = 13.4$ and $J = 10.6$ Hz, H α), 1.49 (d, 3H, $J = 7.1$ Hz, C₄-CH₃); $^{13}\text{C-NMR}$ (CDCl_3) δ 167.0 (C-3), 159.1 (C-6), 149.0 (C-11a), 148.0 (C-10a), 134.0 (C-4'), 133.3 (C-9), 128.1 (C-2',6'), 127.9 (C-1'), 127.8 (C-3',5'), 126.4 (C-7), 126.0 (C-8), 125.5 (C-10), 119.1 (C-6a), 55.4 (C-1), 52.5 (C-4), 36.6 (C α), 15.5 (C₄-CH₃). Anal. Calcd. for C₁₉H₁₆ClN₃O₂: C, 64.50; H, 4.56; N, 11.88. Found: C, 64.39; H, 4.61; N, 11.65.

Compound (15k). Yield, 0.013 g, 33%; colorless oil; IR (KBr) ν 2924.3 (NH), 1681.7 (CO) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 7.39-7.19 (m, 4H, H-2',3',5',6'), 6.37 (sa, 1H, NH), 5.09 (q, 1H, $J = 7.1$ Hz, H-4), 4.69-4.60 (m, 1H, H-1), 3.38 (dd, 1H, $J = 13.5$ and $J = 3.8$ Hz, H α), 3.05 (dd, 1H, $J = 13.4$ and $J = 9.8$ Hz, H α), 2.67-2.53 (m, 4H, H-7,10), 1.86-1.72 (m, 4H, H-8,9), 1.40 (d, 3H, $J = 7.1$ Hz, C₄-CH₃); $^{13}\text{C-NMR}$ (CDCl_3) δ 169.9 (C-3), 161.7 (C-6), 152.8 (C-11a), 152.0 (C-10a), 136.4 (C-1'), 130.9 (C-2',6'), 130.5 (C-3',5'), 129.0 (C-4'), 121.4 (C-6a), 58.0 (C-1), 52.0 (C-4), 44.5 (C α), 31.8 (C-9), 22.7 (C-7), 22.4 (C-8), 22.0 (C-10), 20.2 (C₄-CH₃). Anal. Calc. for C₁₉H₂₀ClN₃O₂: C, 63.77; H, 5.63; N, 11.74. Found: C, 63.84; H, 5.69; N, 11.70.

Compound (16). Yield, 0.009 g, 30%; colorless oil; IR (KBr) ν 2925.3 (NH), 1683.5 (CO) cm^{-1} ; $^1\text{H-NMR}$ (CDCl_3) δ 8.31 (d, 1H, $J = 8.0$ Hz, H-7), 7.82-7.75 (m, 2H, H-9,10), 7.54 (t, 1H, $J = 7.9$ Hz, H-8), 7.45-7.29 (m, 4H, H-2',3',5',6'), 5.81 (br s, 1H, NH), 5.47 (q, 1H, $J = 6.8$ Hz, H-4), 4.85-4.79 (m, 1H, H-1), 3.02-2.92 (m, 2H, H α), 1.65 (d, 3H, $J = 6.8$ Hz, C₄-CH₃); $^{13}\text{C-NMR}$ (CDCl_3) δ 165.0 (C-3), 158.6 (C-6), 148.1 (C-11a), 147.0 (C-10a), 139.7 (C-1'), 133.2 (C-9), 128.0 (C-2',6'), 127.8 (C-3',5'), 127.3 (C-4'), 126.1 (C-7), 125.5 (C-8), 125.3 (C-10), 118.6 (C-6a), 58.4 (C-1), 52.3 (C-4), 44.6 (C α), 17.2 (C₄-CH₃). Anal. Calcd. for C₁₉H₁₆ClN₃O₂: C, 64.50; H, 4.56; N, 11.88. Found: C, 64.42; H, 4.41; N, 11.78.

(3S,6S)-3-(4-Methoxybenzylidene)-6-methylpiperazine-2,5-dione (18). Obtained following the general procedure from **17**^{12a} (0.114 g, 0.463 mmol) and 10% Pd-C (0.027 g) in EtOH (10 mL), in 2 h. Yield 0.083 g, 73%; white solid (after chromatography eluting with 1:2 EtOAc/petroleum ether); mp: 225-227 °C; $[\alpha]_{\text{D}}^{25} = +17.2$ (c 0.14, DMSO); IR (KBr) ν 3191.2 and 3052.9 (NH), 1677.1 (CO), 1256.5 (OCH₃) cm^{-1} ; $^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ 8.09 (br s, 1H, H-4), 8.01 (br s, 1H, H-1), 7.05 (d, 2H, $J = 7.8$ Hz, H-2',6'), 6.84 (d, 2H, $J = 7.8$ Hz, H-3',5'), 4.12-4.10 (m, 1H, H-3), 3.69 (s, 3H, OCH₃), 3.01 (q, 1H, $J = 7.0$ Hz, H-6), 3.05 (dd, 1H, $J = 13.4$ and $J = 3.2$ Hz, H α), 2.77 (dd, 1H, $J = 13.4$ and $J = 5.0$ Hz, H α), 0.51 (d, 3H, $J = 7.0$ Hz, C₆-CH₃); $^{13}\text{C-NMR}$ ($\text{DMSO-}d_6$) δ 167.6 (C-5), 165.8 (C-2), 158.1 (C-4'), 131.3 (C-2',6'), 127.8 (C-1'), 113.4 (C-3',5'), 55.4 (OCH₃), 55.0 (C-3), 49.6 (C-6), 37.3 (C α), 19.7 (C₆-CH₃). Anal. Calc. for C₁₃H₁₆N₂O₃: C, 62.89; H, 6.50; N, 11.28. Found: C, 62.73; H, 6.49; N, 11.22.

Acknowledgements

Financial support from MICINN (grant CTQ2009-12320-BQU) and UCM (Grupos de Investigación, grant 920234) is gratefully acknowledged.

References and Notes

1. For reviews, see: (a) Mhaske, S. B.; Argade, N. P. *Tetrahedron* **2006**, *62*, 9787. (b) Eguchi, S. *Top. Heterocycl. Chem.* **2006**, *6*, 113.
2. For a review, see: Avendaño, C.; Menéndez, J. C. *Curr. Org. Chem.* **2003**, *7*, 149.
3. (a) Penn, J.; Mantle, P. G.; Bilton, J. N.; Sheppard, R. N. *J. Chem. Soc., Perkin Trans. I* **1992**, 1495. (b) For the synthesis of both enantiomers of glyantriline, see: Cledera, P.; Avendaño, C.; Menéndez, J. C. *J. Org. Chem.* **2000**, *65*, 1743.
4. (a) Numata, A.; Takahashi, C.; Matsushita, T.; Miyamoto, T.; Kawai, K.; Usami, Y.; Matsumura, E.; Inoue, M.; Ohishi, H.; Shingu, T. *Tetrahedron Lett.* **1992**, *33*, 1621. (b) Takahashi, C.; Matsushita, T.; Doi, M.; Minoura, K.; Shingu, T.; Kumeda, Y.; Numata, A. *J. Chem. Soc. Perkin Trans. I* **1995**, 2345.
5. (a) Wong, S.-M.; Musza, L. L.; Kydd, G. C.; Kullnig, R.; Gillum, A. M.; Cooper, R. *J. Antibiotics* **1993**, *46*, 545. (b) Fujimoto, H.; Negishi, E.; Yamaguchi, K.; Nishi, N.; Yamazaki, M. *Chem. Pharm. Bull.* **1996**, *44*, 1843.
6. (a) Hochlowski, J. E.; Mullally, M. M.; Spanton, S. G.; Whittern, D. N.; Hill, P.; McAlpine, J. B., *J. Antibiot.* **1993**, *46*, 380. (b) For the synthesis of *N*-acetylardeemin, see: Depew, K. M.; Marsden, S. P.; Zatorska, D.; Zatorski, A.; Bornmann, W. G.; Danishefsky, S. J. *J. Am. Chem. Soc.* **1999**, *121*, 11953.
7. Karwowski, J. P.; Jackson, M.; Rasmussen, R. R.; Humphrey, P. E.; Poddig, J. B.; Kohl, W. L.; Scherr, M. H.; Kadam, S.; McAlpine, J. B., *J. Antibiot.* **1993**, *46*, 374.
8. For reviews of MDR inhibitors, see: (a) Avendaño, C.; Menéndez, J. C. *Curr. Med. Chem.* **2002**, *9*, 159. (b) Avendaño, C.; Menéndez, J. C. *Med. Chem. Rev. Online*, **2004**, *1*, 419.
9. Chou, T. C.; Depew, K. M.; Zheng, Y. H.; Safer, M. L.; Chan, D.; Helfrich, B.; Zatorska, D.; Zatorski, A.; Bornmann, W.; Danishefsky, S. J. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 8369.
10. (a) Méndez-Vidal, C.; Quesada, A. R. *Cancer Lett.* **1998**, *132*, 45. (b) Avendaño, C.; Caballero, E.; Méndez-Vidal, C.; Quesada, A. R.; Menéndez, J. C. *Lett. Drug Des. Discov.* **2006**, *3*, 369.
11. Chou, T.-C.; Bertino, J. R.; Danishefsky, S. J.; Kahan, B. D. U. S. Patent 6,355,639 (March 12, 2002).
12. (a) Cledera, P.; Avendaño, C.; Menéndez, J. C. *Tetrahedron* **1998**, *54*, 12349. (b) Cledera, P.; Sánchez, J. D.; Caballero, E.; Yates, T.; Ramírez, E. G.; Avendaño, C.; Ramos, M. T.; Menéndez, J. C. *Synthesis* **2007**, 3390.
13. Rajappa, S.; Advani, B. G. *J. Chem. Soc., Perkin Trans. I* **1974**, 2122.

14. (a) Martín-Santamaría, S.; Buenadicha, F. L.; Espada, M.; Söllhuber, M. M.; Avendaño, C. *J. Org. Chem.* **1997**, *62*, 6424. (b) Martín-Santamaría, S.; Espada, M.; Avendaño, C. *Tetrahedron* **1997**, *53*, 16795. (c) Heredia, M. L.; Fernández, M.; Cuesta, E.; Avendaño, C. *Tetrahedron: Asymmetry* **2001**, *12*, 411.
15. For one earlier, isolated example of this reaction, see: Heredia, M. L.; Cuesta, E.; Avendaño, C. *Tetrahedron*, **2001**, *57*, 1987.
16. For a review of the captodative effect in α -amino acids, see: Easton, C. J. *Chem. Rev.* **1997**, *97*, 53.
17. The source of oxygen must have been the argon used as “inert” atmosphere. For an account describing unexpected effects due to the presence of oxygen in a reaction carried out under an argon atmosphere, see: Scheiber, S. L.; Ragan, J. A.; Standaert, R. F., in Lindberg, T. (ed.) *Strategies and Tactics in Organic Synthesis*, vol. 3, chapter 11. Academic Press (San Diego), 1991.
18. Halliwell, B.; Gutteridge, J. M. C. *Free Radicals in Biology and Medicine*, 3rd Ed. p. 601. Oxford University Press, 1999.
19. (a) Beak, P.; Brubaker, G. R.; Farney, R. F. *J. Am. Chem. Soc.*, **1976**, *98*, 3621. (b) Wiberg, K. B.; Bailey, W. F. *J. Org. Chem.* **2002**, *67*, 5365.
20. (a) Gallina, C.; Liberatori, A. *Tetrahedron Lett.* **1973**, *14*, 1135. (b) Gallina, C.; Liberatori, A. *Tetrahedron*, **1974**, *30*, 667.
21. However, a detailed study carried out by the Kobayashi group in the context of a total synthesis of neoechinulin A using chiral HPLC as the quantitation method showed a small degree of racemization for this type of reactions. See: Aoki, T. Kamisuki, S.; Kimoto, M.; Ohnishi, K.; Takakusagi, Y.; Kuramochi, K.; Takeda, Y.; Nakazaki, A.; Kuroiwa, K.; Ohuchi, T.; Sugawara, F.; Arai, T.; Kobayashi, S. *Synlett* **2006**, 677.
22. Grahl-Nielsen, O. *Tetrahedron Lett.* **1969**, *10*, 2827.
23. There are two previous literature examples of the partial reduction of the benzene ring in pyrazino[2,1-*b*]quinazoline-3,6-diones, although in an acidic reaction medium. See: (a) Bartolomé, M. T.; Buenadicha, F. L.; Avendaño, C.; Söllhuber, M. *Tetrahedron: Asymmetry* **1998**, *9*, 249. (b) Buenadicha, F. L.; Bartolomé, M. T.; Aguirre, M. J.; Avendaño, C.; Söllhuber, M. M. *Tetrahedron: Asymmetry* **1998**, *9*, 483.
24. The 2-benzyl and 2-(4-methoxybenzyl) analogues of **4** are known in the literature, and showed similar optical rotation values to our compound (see reference 22b).